Ignite Creation Date:
2025-12-24 @ 5:08 PM
Ignite Modification Date:
2026-04-11 @ 12:59 AM
Study NCT ID:
NCT02833350
Status:
COMPLETED
Last Update Posted:
2020-06-12
First Post:
2016-07-12
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['Chile']}, 'conditionBrowseModule': {'meshes': [{'id': 'D001172', 'term': 'Arthritis, Rheumatoid'}], 'ancestors': [{'id': 'D001168', 'term': 'Arthritis'}, {'id': 'D007592', 'term': 'Joint Diseases'}, {'id': 'D009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D012216', 'term': 'Rheumatic Diseases'}, {'id': 'D003240', 'term': 'Connective Tissue Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000619415', 'term': 'fenebrutinib'}, {'id': 'D000068879', 'term': 'Adalimumab'}, {'id': 'D005492', 'term': 'Folic Acid'}], 'ancestors': [{'id': 'D061067', 'term': 'Antibodies, Monoclonal, Humanized'}, {'id': 'D000911', 'term': 'Antibodies, Monoclonal'}, {'id': 'D000906', 'term': 'Antibodies'}, {'id': 'D007136', 'term': 'Immunoglobulins'}, {'id': 'D007162', 'term': 'Immunoproteins'}, {'id': 'D001798', 'term': 'Blood Proteins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D012712', 'term': 'Serum Globulins'}, {'id': 'D005916', 'term': 'Globulins'}, {'id': 'D011622', 'term': 'Pterins'}, {'id': 'D011621', 'term': 'Pteridines'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'genentech@druginfo.com', 'phone': '800 821-8590', 'title': 'Medical Communications', 'organization': 'Hoffmann-La Roche'}, 'certainAgreement': {'otherDetails': "The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.", 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'From randomization to end of study (approximately 22 months)', 'eventGroups': [{'id': 'EG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.', 'otherNumAtRisk': 40, 'deathsNumAtRisk': 40, 'otherNumAffected': 9, 'seriousNumAtRisk': 40, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.', 'otherNumAtRisk': 109, 'deathsNumAtRisk': 109, 'otherNumAffected': 18, 'seriousNumAtRisk': 109, 'deathsNumAffected': 0, 'seriousNumAffected': 1}, {'id': 'EG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.', 'otherNumAtRisk': 110, 'deathsNumAtRisk': 110, 'otherNumAffected': 11, 'seriousNumAtRisk': 110, 'deathsNumAffected': 1, 'seriousNumAffected': 3}, {'id': 'EG003', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.', 'otherNumAtRisk': 110, 'deathsNumAtRisk': 110, 'otherNumAffected': 15, 'seriousNumAtRisk': 110, 'deathsNumAffected': 0, 'seriousNumAffected': 1}, {'id': 'EG004', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.', 'otherNumAtRisk': 111, 'deathsNumAtRisk': 111, 'otherNumAffected': 16, 'seriousNumAtRisk': 111, 'deathsNumAffected': 0, 'seriousNumAffected': 2}, {'id': 'EG005', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.', 'otherNumAtRisk': 49, 'deathsNumAtRisk': 49, 'otherNumAffected': 3, 'seriousNumAtRisk': 49, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG006', 'title': 'Cohort 2: GDC-0853 Placebo', 'description': 'Participants of Cohort 2 received placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.', 'otherNumAtRisk': 49, 'deathsNumAtRisk': 49, 'otherNumAffected': 7, 'seriousNumAtRisk': 49, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'NAUSEA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 40, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 109, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 110, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 110, 'numEvents': 6, 'numAffected': 5}, {'groupId': 'EG004', 'numAtRisk': 111, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 4, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 49, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 21.0'}, {'term': 'VOMITING', 'stats': [{'groupId': 'EG000', 'numAtRisk': 40, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 109, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 110, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 110, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 111, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 21.0'}, {'term': 'UPPER RESPIRATORY TRACT INFECTION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 109, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 110, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 110, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 111, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 21.0'}, {'term': 'URINARY TRACT INFECTION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 40, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 109, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 110, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 110, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 111, 'numEvents': 10, 'numAffected': 8}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 49, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 21.0'}, {'term': 'ALANINE AMINOTRANFERASE INCREASED', 'stats': [{'groupId': 'EG000', 'numAtRisk': 40, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 109, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 110, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 110, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 111, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 21.0'}, {'term': 'ASPARTATE AMINOTRANSFERASE INCREASED', 'stats': [{'groupId': 'EG000', 'numAtRisk': 40, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 109, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 110, 'numEvents': 4, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 110, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 111, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 21.0'}, {'term': 'HEADACHE', 'stats': [{'groupId': 'EG000', 'numAtRisk': 40, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 109, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 110, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 110, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG004', 'numAtRisk': 111, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 21.0'}, {'term': 'ANXIETY', 'stats': [{'groupId': 'EG000', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 109, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 110, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 110, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 111, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 49, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 21.0'}], 'seriousEvents': [{'term': 'MYOCARDIAL INFARCTION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 109, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 110, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 110, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 111, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49}, {'groupId': 'EG006', 'numAtRisk': 49}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 21.0'}, {'term': 'SMALL INTESTINAL DISORDERS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 109, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 110, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 110, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 111, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 21.0'}, {'term': 'CELLULITS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 109, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 110, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 110, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 111, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 21.0'}, {'term': 'PNEUMONIA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 109, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 110, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 110, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 111, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 21.0'}, {'term': 'PYELONEPHRITIS OBSTRUCTION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 109, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 110, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 110, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 111, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 21.0'}, {'term': 'SEIZURE', 'stats': [{'groupId': 'EG000', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 109, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 110, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 110, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 111, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 21.0'}, {'term': 'CHRONIC OBSTRUCTIVE PULMONARY DISEASE', 'stats': [{'groupId': 'EG000', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 109, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 110, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 110, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 111, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 21.0'}, {'term': 'PLEURAL EFFUSION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 109, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 110, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 110, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 111, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA version 21.0'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Day 84, Comparison Between GDC-0853 and Placebo (Cohort 1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '111', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG003', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG004', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'categories': [{'measurements': [{'value': '17.5', 'groupId': 'OG000', 'lowerLimit': '5.72', 'upperLimit': '29.28'}, {'value': '27.5', 'groupId': 'OG001', 'lowerLimit': '19.14', 'upperLimit': '35.91'}, {'value': '34.5', 'groupId': 'OG002', 'lowerLimit': '25.66', 'upperLimit': '43.43'}, {'value': '14.5', 'groupId': 'OG003', 'lowerLimit': '7.96', 'upperLimit': '21.13'}, {'value': '36.0', 'groupId': 'OG004', 'lowerLimit': '27.10', 'upperLimit': '44.97'}]}]}], 'analyses': [{'pValue': '0.2503', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Weighted difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '8.00', 'ciLowerLimit': '-5.64', 'ciUpperLimit': '21.64', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0164', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Weighted difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '12.93', 'ciLowerLimit': '2.37', 'ciUpperLimit': '23.48', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0003', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Weighted difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '20.00', 'ciLowerLimit': '9.21', 'ciUpperLimit': '30.79', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Day 84', 'description': "ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \\[either C-reactive protein or Erythrocyte Sedimentation Rate\\].", 'unitOfMeasure': 'Percentage', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis. Number of participants for whom data were collected is indicated for each time point.'}, {'type': 'PRIMARY', 'title': 'Percentage of Participants With Adverse Events', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '111', 'groupId': 'OG004'}, {'value': '49', 'groupId': 'OG005'}, {'value': '49', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG003', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG004', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG005', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG006', 'title': 'Cohort 2: GDC-0853 Placebo', 'description': 'Participants of Cohort 2 received placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'categories': [{'measurements': [{'value': '37.5', 'groupId': 'OG000'}, {'value': '42.2', 'groupId': 'OG001'}, {'value': '50.9', 'groupId': 'OG002'}, {'value': '45.5', 'groupId': 'OG003'}, {'value': '45.0', 'groupId': 'OG004'}, {'value': '22.4', 'groupId': 'OG005'}, {'value': '44.9', 'groupId': 'OG006'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Day 1 up to 8 weeks after last dose (up to Week 20)', 'description': 'An Adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A SAE was any experience that suggested a significant hazard, contraindication, side effect or precaution that: resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was medically significant.', 'unitOfMeasure': 'Percentage', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety population included all participants according to treatment administered.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Achieving ACR50 Response at Day 84, Comparison Between GDC-0853 and Adalimumab (Cohort 1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '111', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG003', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG004', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'categories': [{'measurements': [{'value': '17.5', 'groupId': 'OG000', 'lowerLimit': '5.72', 'upperLimit': '29.28'}, {'value': '27.5', 'groupId': 'OG001', 'lowerLimit': '19.14', 'upperLimit': '35.91'}, {'value': '34.5', 'groupId': 'OG002', 'lowerLimit': '25.66', 'upperLimit': '43.43'}, {'value': '14.5', 'groupId': 'OG003', 'lowerLimit': '7.96', 'upperLimit': '21.13'}, {'value': '36.0', 'groupId': 'OG004', 'lowerLimit': '27.10', 'upperLimit': '44.97'}]}]}], 'analyses': [{'pValue': '0.1694', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Weighted difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-8.58', 'ciLowerLimit': '-20.82', 'ciUpperLimit': '3.66', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.8132', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Weighted difference', 'ciPctValue': '95', 'paramValue': '-1.50', 'ciLowerLimit': '-13.96', 'ciUpperLimit': '10.95', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Day 84', 'description': "ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \\[either C-reactive protein or Erythrocyte Sedimentation Rate\\].", 'unitOfMeasure': 'Percentage', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis. Number of participants for whom data were collected is indicated for each time point.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Achieving ACR50 Response at Day 84, Comparison Between GDC-0853 and Placebo (Cohort 2)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '50', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 2: GDC-0853 Placebo', 'description': 'Participants of Cohort 2 received placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'categories': [{'measurements': [{'value': '25.0', 'groupId': 'OG000', 'lowerLimit': '12.75', 'upperLimit': '37.25'}, {'value': '12.0', 'groupId': 'OG001', 'lowerLimit': '2.99', 'upperLimit': '21.01'}]}]}], 'analyses': [{'pValue': '0.0717', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Weighted difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '13.7', 'ciLowerLimit': '-1.21', 'ciUpperLimit': '28.61', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Day 84', 'description': "ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \\[either C-reactive protein or Erythrocyte Sedimentation Rate\\].", 'unitOfMeasure': 'Percentage', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis. Number of participants for whom data were collected is indicated for each time point.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '111', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG003', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG004', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG005', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG006', 'title': 'Cohort 2: GDC-0853 Placebo', 'description': 'Participants of Cohort 2 received placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'title': 'Week 1 Day 7', 'categories': [{'measurements': [{'value': '10.0', 'groupId': 'OG000', 'lowerLimit': '.70', 'upperLimit': '19.3'}, {'value': '14.7', 'groupId': 'OG001', 'lowerLimit': '8.04', 'upperLimit': '21.32'}, {'value': '13.6', 'groupId': 'OG002', 'lowerLimit': '7.22', 'upperLimit': '20.05'}, {'value': '10.0', 'groupId': 'OG003', 'lowerLimit': '4.39', 'upperLimit': '15.61'}, {'value': '25.2', 'groupId': 'OG004', 'lowerLimit': '17.15', 'upperLimit': '33.30'}, {'value': '22.9', 'groupId': 'OG005', 'lowerLimit': '11.03', 'upperLimit': '34.81'}, {'value': '2.0', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '5.88'}]}]}, {'title': 'Week 2 Day 14', 'categories': [{'measurements': [{'value': '12.5', 'groupId': 'OG000', 'lowerLimit': '2.25', 'upperLimit': '22.75'}, {'value': '19.3', 'groupId': 'OG001', 'lowerLimit': '11.86', 'upperLimit': '26.67'}, {'value': '27.3', 'groupId': 'OG002', 'lowerLimit': '18.95', 'upperLimit': '35.60'}, {'value': '16.4', 'groupId': 'OG003', 'lowerLimit': '9.45', 'upperLimit': '23.28'}, {'value': '48.6', 'groupId': 'OG004', 'lowerLimit': '39.35', 'upperLimit': '57.95'}, {'value': '25.0', 'groupId': 'OG005', 'lowerLimit': '12.75', 'upperLimit': '37.25'}, {'value': '10.0', 'groupId': 'OG006', 'lowerLimit': '1.68', 'upperLimit': '18.32'}]}]}, {'title': 'Week 4 Day 28', 'categories': [{'measurements': [{'value': '30.0', 'groupId': 'OG000', 'lowerLimit': '15.80', 'upperLimit': '44.20'}, {'value': '34.9', 'groupId': 'OG001', 'lowerLimit': '25.92', 'upperLimit': '43.81'}, {'value': '41.8', 'groupId': 'OG002', 'lowerLimit': '32.60', 'upperLimit': '51.04'}, {'value': '25.5', 'groupId': 'OG003', 'lowerLimit': '17.31', 'upperLimit': '33.59'}, {'value': '59.5', 'groupId': 'OG004', 'lowerLimit': '50.33', 'upperLimit': '68.59'}, {'value': '35.4', 'groupId': 'OG005', 'lowerLimit': '21.89', 'upperLimit': '48.95'}, {'value': '24.0', 'groupId': 'OG006', 'lowerLimit': '12.16', 'upperLimit': '35.84'}]}]}, {'title': 'Week 8 Day 56', 'categories': [{'measurements': [{'value': '50.0', 'groupId': 'OG000', 'lowerLimit': '34.51', 'upperLimit': '65.49'}, {'value': '52.3', 'groupId': 'OG001', 'lowerLimit': '42.92', 'upperLimit': '61.67'}, {'value': '58.2', 'groupId': 'OG002', 'lowerLimit': '48.96', 'upperLimit': '67.40'}, {'value': '37.3', 'groupId': 'OG003', 'lowerLimit': '28.24', 'upperLimit': '46.31'}, {'value': '71.2', 'groupId': 'OG004', 'lowerLimit': '62.74', 'upperLimit': '79.60'}, {'value': '47.9', 'groupId': 'OG005', 'lowerLimit': '33.78', 'upperLimit': '62.05'}, {'value': '18.0', 'groupId': 'OG006', 'lowerLimit': '7.35', 'upperLimit': '28.65'}]}]}, {'title': 'Week 12 Day 84', 'categories': [{'measurements': [{'value': '60.0', 'groupId': 'OG000', 'lowerLimit': '44.82', 'upperLimit': '75.18'}, {'value': '56.0', 'groupId': 'OG001', 'lowerLimit': '46.64', 'upperLimit': '65.28'}, {'value': '59.1', 'groupId': 'OG002', 'lowerLimit': '49.90', 'upperLimit': '68.28'}, {'value': '36.4', 'groupId': 'OG003', 'lowerLimit': '27.37', 'upperLimit': '45.35'}, {'value': '72.1', 'groupId': 'OG004', 'lowerLimit': '63.73', 'upperLimit': '80.42'}, {'value': '58.3', 'groupId': 'OG005', 'lowerLimit': '44.39', 'upperLimit': '72.28'}, {'value': '24.0', 'groupId': 'OG006', 'lowerLimit': '12.16', 'upperLimit': '35.84'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': "ACR20 response is defined as a ≥ 20% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \\[either C-reactive protein or Erythrocyte Sedimentation Rate\\]", 'unitOfMeasure': 'Percentage', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis. Number of participants for whom data were collected is indicated for each time point.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '111', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG003', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG004', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG005', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG006', 'title': 'Cohort 2: GDC-0853 Placebo', 'description': 'Participants of Cohort 2 received placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'title': 'Week 1 Day 7', 'categories': [{'measurements': [{'value': '2.5', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '7.34'}, {'value': '2.8', 'groupId': 'OG001', 'lowerLimit': '0.00', 'upperLimit': '5.82'}, {'value': '3.6', 'groupId': 'OG002', 'lowerLimit': '0.14', 'upperLimit': '7.13'}, {'value': '2.7', 'groupId': 'OG003', 'lowerLimit': '0.00', 'upperLimit': '5.77'}, {'value': '4.5', 'groupId': 'OG004', 'lowerLimit': '0.65', 'upperLimit': '8.36'}, {'value': '6.3', 'groupId': 'OG005', 'lowerLimit': '0.00', 'upperLimit': '13.10'}, {'value': '2.0', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '5.88'}]}]}, {'title': 'Week 2 Day 14', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '1.8', 'groupId': 'OG001', 'lowerLimit': '0.00', 'upperLimit': '4.35'}, {'value': '7.3', 'groupId': 'OG002', 'lowerLimit': '2.42', 'upperLimit': '12.13'}, {'value': '2.7', 'groupId': 'OG003', 'lowerLimit': '0.00', 'upperLimit': '5.77'}, {'value': '9.0', 'groupId': 'OG004', 'lowerLimit': '3.68', 'upperLimit': '14.34'}, {'value': '10.4', 'groupId': 'OG005', 'lowerLimit': '1.77', 'upperLimit': '19.06'}, {'value': '0.00', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '0.00'}]}]}, {'title': 'Week 4 day 28', 'categories': [{'measurements': [{'value': '5.0', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '11.75'}, {'value': '9.2', 'groupId': 'OG001', 'lowerLimit': '3.76', 'upperLimit': '14.59'}, {'value': '10.0', 'groupId': 'OG002', 'lowerLimit': '4.39', 'upperLimit': '15.61'}, {'value': '6.4', 'groupId': 'OG003', 'lowerLimit': '1.80', 'upperLimit': '10.93'}, {'value': '25.2', 'groupId': 'OG004', 'lowerLimit': '17.15', 'upperLimit': '33.30'}, {'value': '10.4', 'groupId': 'OG005', 'lowerLimit': '1.77', 'upperLimit': '19.06'}, {'value': '6.0', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '12.58'}]}]}, {'title': 'Week 8 Day 56', 'categories': [{'measurements': [{'value': '15.0', 'groupId': 'OG000', 'lowerLimit': '3.93', 'upperLimit': '26.07'}, {'value': '18.3', 'groupId': 'OG001', 'lowerLimit': '11.08', 'upperLimit': '25.62'}, {'value': '22.7', 'groupId': 'OG002', 'lowerLimit': '14.9', 'upperLimit': '30.56'}, {'value': '17.3', 'groupId': 'OG003', 'lowerLimit': '10.21', 'upperLimit': '24.34'}, {'value': '32.4', 'groupId': 'OG004', 'lowerLimit': '23.72', 'upperLimit': '41.14'}, {'value': '22.9', 'groupId': 'OG005', 'lowerLimit': '11.03', 'upperLimit': '34.81'}, {'value': '10.0', 'groupId': 'OG006', 'lowerLimit': '1.68', 'upperLimit': '18.32'}]}]}, {'title': 'Week 12 Day 84', 'categories': [{'measurements': [{'value': '17.5', 'groupId': 'OG000', 'lowerLimit': '5.72', 'upperLimit': '29.28'}, {'value': '27.5', 'groupId': 'OG001', 'lowerLimit': '19.14', 'upperLimit': '35.91'}, {'value': '34.5', 'groupId': 'OG002', 'lowerLimit': '25.66', 'upperLimit': '43.43'}, {'value': '14.5', 'groupId': 'OG003', 'lowerLimit': '7.96', 'upperLimit': '21.13'}, {'value': '36.0', 'groupId': 'OG004', 'lowerLimit': '27.10', 'upperLimit': '44.97'}, {'value': '25.0', 'groupId': 'OG005', 'lowerLimit': '12.75', 'upperLimit': '37.25'}, {'value': '12.0', 'groupId': 'OG006', 'lowerLimit': '2.99', 'upperLimit': '21.01'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': "ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \\[either C-reactive protein or Erythrocyte Sedimentation Rate\\].", 'unitOfMeasure': 'Percentage', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis. Number of participants for whom data were collected is indicated for each time point.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '111', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG003', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG004', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG005', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG006', 'title': 'Cohort 2: GDC-0853 Placebo', 'description': 'Participants of Cohort 2 received placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'title': 'Week 1 Day 7', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.9', 'groupId': 'OG001', 'lowerLimit': '0.00', 'upperLimit': '2.71'}, {'value': '0.9', 'groupId': 'OG002', 'lowerLimit': '0.00', 'upperLimit': '2.68'}, {'value': '0.0', 'groupId': 'OG003', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG004', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG005', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '0.00'}]}]}, {'title': 'Week 2 Day 14', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.9', 'groupId': 'OG001', 'lowerLimit': '0.00', 'upperLimit': '2.71'}, {'value': '0.0', 'groupId': 'OG002', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.00', 'groupId': 'OG003', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '3.6', 'groupId': 'OG004', 'lowerLimit': '0.14', 'upperLimit': '7.07'}, {'value': '4.2', 'groupId': 'OG005', 'lowerLimit': '0.00', 'upperLimit': '9.82'}, {'value': '0.0', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '0.00'}]}]}, {'title': 'Week 4 Day 28', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '2.8', 'groupId': 'OG001', 'lowerLimit': '0.00', 'upperLimit': '5.82'}, {'value': '4.5', 'groupId': 'OG002', 'lowerLimit': '0.65', 'upperLimit': '8.44'}, {'value': '0.9', 'groupId': 'OG003', 'lowerLimit': '0.00', 'upperLimit': '2.68'}, {'value': '6.3', 'groupId': 'OG004', 'lowerLimit': '1.78', 'upperLimit': '10.83'}, {'value': '2.1', 'groupId': 'OG005', 'lowerLimit': '0.00', 'upperLimit': '6.12'}, {'value': '2.0', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '5.88'}]}]}, {'title': 'Week 8 Day 56', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '7.3', 'groupId': 'OG001', 'lowerLimit': '2.44', 'upperLimit': '12.24'}, {'value': '9.1', 'groupId': 'OG002', 'lowerLimit': '3.72', 'upperLimit': '14.46'}, {'value': '3.6', 'groupId': 'OG003', 'lowerLimit': '0.14', 'upperLimit': '7.13'}, {'value': '14.4', 'groupId': 'OG004', 'lowerLimit': '7.88', 'upperLimit': '20.95'}, {'value': '6.3', 'groupId': 'OG005', 'lowerLimit': '0.00', 'upperLimit': '13.10'}, {'value': '4.0', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '9.43'}]}]}, {'title': 'Week 12 Day 84', 'categories': [{'measurements': [{'value': '5.0', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '11.75'}, {'value': '9.2', 'groupId': 'OG001', 'lowerLimit': '3.76', 'upperLimit': '14.59'}, {'value': '12.7', 'groupId': 'OG002', 'lowerLimit': '6.50', 'upperLimit': '18.96'}, {'value': '7.3', 'groupId': 'OG003', 'lowerLimit': '2.42', 'upperLimit': '12.13'}, {'value': '18.0', 'groupId': 'OG004', 'lowerLimit': '10.87', 'upperLimit': '25.17'}, {'value': '14.6', 'groupId': 'OG005', 'lowerLimit': '4.60', 'upperLimit': '24.57'}, {'value': '4.0', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '9.43'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': "ACR70 response is defined as a ≥ 70% improvement (reduction) compared with Baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \\[either C-reactive protein or Erythrocyte Sedimentation Rate\\].", 'unitOfMeasure': 'Percentage', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis. Number of participants for whom data were collected is indicated for each time point.'}, {'type': 'SECONDARY', 'title': 'Change in Disease Activity Score From Baseline Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '111', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG003', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG004', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG005', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG006', 'title': 'Cohort 2: GDC-0853 Placebo', 'description': 'Participants of Cohort 2 received placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'title': 'Week 1 Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '37', 'groupId': 'OG000'}, {'value': '106', 'groupId': 'OG001'}, {'value': '107', 'groupId': 'OG002'}, {'value': '109', 'groupId': 'OG003'}, {'value': '107', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '46', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-0.34', 'spread': '0.60', 'groupId': 'OG000'}, {'value': '-0.35', 'spread': '0.66', 'groupId': 'OG001'}, {'value': '-0.37', 'spread': '0.80', 'groupId': 'OG002'}, {'value': '-0.33', 'spread': '0.84', 'groupId': 'OG003'}, {'value': '-0.92', 'spread': '0.71', 'groupId': 'OG004'}, {'value': '-0.49', 'spread': '0.84', 'groupId': 'OG005'}, {'value': '-0.36', 'spread': '0.63', 'groupId': 'OG006'}]}]}, {'title': 'Week 2 Day 14', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}, {'value': '106', 'groupId': 'OG001'}, {'value': '108', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '109', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-0.47', 'spread': '0.72', 'groupId': 'OG000'}, {'value': '-0.63', 'spread': '0.84', 'groupId': 'OG001'}, {'value': '-0.70', 'spread': '0.80', 'groupId': 'OG002'}, {'value': '-.54', 'spread': '0.90', 'groupId': 'OG003'}, {'value': '-1.09', 'spread': '0.81', 'groupId': 'OG004'}, {'value': '-0.65', 'spread': '0.87', 'groupId': 'OG005'}, {'value': '-0.45', 'spread': '0.69', 'groupId': 'OG006'}]}]}, {'title': 'Week 4 Day 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '37', 'groupId': 'OG000'}, {'value': '103', 'groupId': 'OG001'}, {'value': '105', 'groupId': 'OG002'}, {'value': '105', 'groupId': 'OG003'}, {'value': '109', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '48', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-0.75', 'spread': '0.86', 'groupId': 'OG000'}, {'value': '-0.90', 'spread': '0.96', 'groupId': 'OG001'}, {'value': '-0.91', 'spread': '0.97', 'groupId': 'OG002'}, {'value': '-0.62', 'spread': '1.04', 'groupId': 'OG003'}, {'value': '-1.45', 'spread': '0.87', 'groupId': 'OG004'}, {'value': '-0.77', 'spread': '0.90', 'groupId': 'OG005'}, {'value': '-0.44', 'spread': '0.84', 'groupId': 'OG006'}]}]}, {'title': 'Week 8 Day 56', 'denoms': [{'units': 'Participants', 'counts': [{'value': '36', 'groupId': 'OG000'}, {'value': '100', 'groupId': 'OG001'}, {'value': '103', 'groupId': 'OG002'}, {'value': '100', 'groupId': 'OG003'}, {'value': '106', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '45', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-1.14', 'spread': '0.90', 'groupId': 'OG000'}, {'value': '-1.35', 'spread': '1.12', 'groupId': 'OG001'}, {'value': '-1.37', 'spread': '1.11', 'groupId': 'OG002'}, {'value': '-1.08', 'spread': '1.19', 'groupId': 'OG003'}, {'value': '-1.75', 'spread': '0.98', 'groupId': 'OG004'}, {'value': '-1.33', 'spread': '0.98', 'groupId': 'OG005'}, {'value': '-0.56', 'spread': '0.87', 'groupId': 'OG006'}]}]}, {'title': 'Week 12 Day 84', 'denoms': [{'units': 'Participants', 'counts': [{'value': '37', 'groupId': 'OG000'}, {'value': '97', 'groupId': 'OG001'}, {'value': '97', 'groupId': 'OG002'}, {'value': '102', 'groupId': 'OG003'}, {'value': '106', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '44', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-1.30', 'spread': '0.95', 'groupId': 'OG000'}, {'value': '-1.72', 'spread': '1.11', 'groupId': 'OG001'}, {'value': '-1.70', 'spread': '1.02', 'groupId': 'OG002'}, {'value': '-1.17', 'spread': '1.24', 'groupId': 'OG003'}, {'value': '-1.87', 'spread': '1.02', 'groupId': 'OG004'}, {'value': '-1.62', 'spread': '1.15', 'groupId': 'OG005'}, {'value': '-0.86', 'spread': '1.03', 'groupId': 'OG006'}]}]}], 'analyses': [{'pValue': '0.8504', 'groupIds': ['OG000', 'OG003'], 'paramType': 'adjusted difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.11', 'ciLowerLimit': '-0.45', 'ciUpperLimit': '0.23', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.9884', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.04', 'ciLowerLimit': '-0.28', 'ciUpperLimit': '0.21', 'groupDescription': 'At week 1, Day 7', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.9230', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.06', 'ciLowerLimit': '-0.31', 'ciUpperLimit': '0.18', 'groupDescription': 'Week 1 Day 7', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.9853', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.06', 'ciLowerLimit': '-0.43', 'ciUpperLimit': '0.31', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.6826', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.12', 'ciLowerLimit': '-0.38', 'ciUpperLimit': '0.15', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.2634', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.18', 'ciLowerLimit': '-0.45', 'ciUpperLimit': '0.08', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.2885', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.29', 'ciLowerLimit': '-0.72', 'ciUpperLimit': '0.14', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0598', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.30', 'ciLowerLimit': '-0.61', 'ciUpperLimit': '0.01', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0440', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.31', 'ciLowerLimit': '-0.62', 'ciUpperLimit': '-0.01', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.4271', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.28', 'ciLowerLimit': '-0.76', 'ciUpperLimit': '0.20', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0969', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.31', 'ciLowerLimit': '-0.66', 'ciUpperLimit': '0.04', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0612', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.33', 'ciLowerLimit': '-0.68', 'ciUpperLimit': '0.01', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.2079', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.36', 'ciLowerLimit': '-0.84', 'ciUpperLimit': '0.12', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0003', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.57', 'ciLowerLimit': '-0.92', 'ciUpperLimit': '-0.22', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0003', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.57', 'ciLowerLimit': '-0.92', 'ciUpperLimit': '-0.22', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<.0001', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.58', 'ciLowerLimit': '0.34', 'ciUpperLimit': '0.82', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.0001', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.55', 'ciLowerLimit': '0.31', 'ciUpperLimit': '0.80', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<.0001', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.47', 'ciLowerLimit': '0.20', 'ciUpperLimit': '0.74', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0009', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.40', 'ciLowerLimit': '0.13', 'ciUpperLimit': '0.66', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<.0001', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.56', 'ciLowerLimit': '0.25', 'ciUpperLimit': '0.87', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<.0001', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.55', 'ciLowerLimit': '0.24', 'ciUpperLimit': '0.85', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0095', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.42', 'ciLowerLimit': '0.08', 'ciUpperLimit': '0.76', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0153', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.40', 'ciLowerLimit': '0.06', 'ciUpperLimit': '0.74', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.4839', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.19', 'ciLowerLimit': '-0.16', 'ciUpperLimit': '0.54', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.5035', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.19', 'ciLowerLimit': '-0.16', 'ciUpperLimit': '0.53', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.4286', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.11', 'ciLowerLimit': '-0.38', 'ciUpperLimit': '0.16', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.1831', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.20', 'ciLowerLimit': '-0.50', 'ciUpperLimit': '0.10', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0667', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.31', 'ciLowerLimit': '-0.65', 'ciUpperLimit': '0.02', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.0001', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.77', 'ciLowerLimit': '-1.11', 'ciUpperLimit': '-0.42', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0002', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.76', 'ciLowerLimit': '-1.15', 'ciUpperLimit': '-0.38', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': "The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \\[28 joints\\], swollen joint count (SJC) \\[28 joints\\], patient's global assessment of disease activity \\[visual analog scale: 0=no disease activity to 100=maximum disease activity\\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \\< 2.6.", 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis. Number of participants for whom data were collected is indicated for each time point.'}, {'type': 'SECONDARY', 'title': 'Change in Disease Activity Score From Baseline Based on 28-Joints Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP])', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '111', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG003', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG004', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG005', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG006', 'title': 'Cohort 2: GDC-0853 Placebo', 'description': 'Participants of Cohort 2 received placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'title': 'Week 1 Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '37', 'groupId': 'OG000'}, {'value': '104', 'groupId': 'OG001'}, {'value': '102', 'groupId': 'OG002'}, {'value': '103', 'groupId': 'OG003'}, {'value': '104', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '45', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-0.43', 'spread': '0.67', 'groupId': 'OG000'}, {'value': '-0.48', 'spread': '0.73', 'groupId': 'OG001'}, {'value': '-0.49', 'spread': '0.86', 'groupId': 'OG002'}, {'value': '-0.37', 'spread': '0.91', 'groupId': 'OG003'}, {'value': '-1.10', 'spread': '0.75', 'groupId': 'OG004'}, {'value': '-0.63', 'spread': '0.91', 'groupId': 'OG005'}, {'value': '-.40', 'spread': '0.69', 'groupId': 'OG006'}]}]}, {'title': 'Week 2 Day 14', 'denoms': [{'units': 'Participants', 'counts': [{'value': '37', 'groupId': 'OG000'}, {'value': '103', 'groupId': 'OG001'}, {'value': '105', 'groupId': 'OG002'}, {'value': '105', 'groupId': 'OG003'}, {'value': '107', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '46', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-0.51', 'spread': '0.85', 'groupId': 'OG000'}, {'value': '-0.77', 'spread': '0.86', 'groupId': 'OG001'}, {'value': '-0.84', 'spread': '0.86', 'groupId': 'OG002'}, {'value': '-0.57', 'spread': '1.00', 'groupId': 'OG003'}, {'value': '-1.26', 'spread': '0.89', 'groupId': 'OG004'}, {'value': '-0.81', 'spread': '0.98', 'groupId': 'OG005'}, {'value': '-0.54', 'spread': '0.80', 'groupId': 'OG006'}]}]}, {'title': 'Week 4 Day 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '36', 'groupId': 'OG000'}, {'value': '101', 'groupId': 'OG001'}, {'value': '103', 'groupId': 'OG002'}, {'value': '99', 'groupId': 'OG003'}, {'value': '106', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '48', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-0.88', 'spread': '0.90', 'groupId': 'OG000'}, {'value': '-1.06', 'spread': '1.02', 'groupId': 'OG001'}, {'value': '-1.08', 'spread': '1.03', 'groupId': 'OG002'}, {'value': '-0.65', 'spread': '1.16', 'groupId': 'OG003'}, {'value': '-1.61', 'spread': '0.94', 'groupId': 'OG004'}, {'value': '-0.95', 'spread': '1.04', 'groupId': 'OG005'}, {'value': '-0.55', 'spread': '0.94', 'groupId': 'OG006'}]}]}, {'title': 'Week 8 Day 56', 'denoms': [{'units': 'Participants', 'counts': [{'value': '36', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '100', 'groupId': 'OG002'}, {'value': '97', 'groupId': 'OG003'}, {'value': '103', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '45', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-1.31', 'spread': '0.91', 'groupId': 'OG000'}, {'value': '-1.56', 'spread': '1.21', 'groupId': 'OG001'}, {'value': '-1.57', 'spread': '1.16', 'groupId': 'OG002'}, {'value': '1.20', 'spread': '1.30', 'groupId': 'OG003'}, {'value': '-1.97', 'spread': '1.03', 'groupId': 'OG004'}, {'value': '-1.51', 'spread': '1.05', 'groupId': 'OG005'}, {'value': '-0.67', 'spread': '1.01', 'groupId': 'OG006'}]}]}, {'title': 'Week 12 Day 84', 'denoms': [{'units': 'Participants', 'counts': [{'value': '36', 'groupId': 'OG000'}, {'value': '94', 'groupId': 'OG001'}, {'value': '95', 'groupId': 'OG002'}, {'value': '99', 'groupId': 'OG003'}, {'value': '104', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-1.53', 'spread': '0.95', 'groupId': 'OG000'}, {'value': '-1.97', 'spread': '1.20', 'groupId': 'OG001'}, {'value': '-1.93', 'spread': '1.11', 'groupId': 'OG002'}, {'value': '-1.33', 'spread': '1.33', 'groupId': 'OG003'}, {'value': '-2.06', 'spread': '1.08', 'groupId': 'OG004'}, {'value': '-1.83', 'spread': '1.22', 'groupId': 'OG005'}, {'value': '-1.00', 'spread': '1.11', 'groupId': 'OG006'}]}]}], 'analyses': [{'pValue': '0.5807', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.18', 'ciLowerLimit': '-0.55', 'ciUpperLimit': '0.19', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.6270', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.12', 'ciLowerLimit': '-0.39', 'ciUpperLimit': '0.14', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.4475', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.15', 'ciLowerLimit': '-0.42', 'ciUpperLimit': '0.12', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.9891', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.06', 'ciLowerLimit': '-0.47', 'ciUpperLimit': '0.35', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.2244', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.21', 'ciLowerLimit': '-0.51', 'ciUpperLimit': '0.08', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0586', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.28', 'ciLowerLimit': '-0.58', 'ciUpperLimit': '0.01', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.1338', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.39', 'ciLowerLimit': '-0.85', 'ciUpperLimit': '0.08', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0119', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.40', 'ciLowerLimit': '-0.74', 'ciUpperLimit': '-0.07', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0046', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.44', 'ciLowerLimit': '-0.77', 'ciUpperLimit': '-0.11', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.3943', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.31', 'ciLowerLimit': '-0.82', 'ciUpperLimit': '0.20', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0526', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.37', 'ciLowerLimit': '-0.74', 'ciUpperLimit': '0.00', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0365', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.39', 'ciLowerLimit': '-0.76', 'ciUpperLimit': '-0.02', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.1696', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.41', 'ciLowerLimit': '-0.93', 'ciUpperLimit': '0.11', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0002', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.63', 'ciLowerLimit': '-1.01', 'ciUpperLimit': '-0.25', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0003', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.62', 'ciLowerLimit': '-1.00', 'ciUpperLimit': '-0.24', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.0001', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.64', 'ciLowerLimit': '0.37', 'ciUpperLimit': '0.90', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.0001', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.61', 'ciLowerLimit': '0.34', 'ciUpperLimit': '0.88', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0001', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.50', 'ciLowerLimit': '0.21', 'ciUpperLimit': '0.79', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0012', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.43', 'ciLowerLimit': '0.14', 'ciUpperLimit': '0.72', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.0001', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.58', 'ciLowerLimit': '0.25', 'ciUpperLimit': '0.91', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0002', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.54', 'ciLowerLimit': '0.21', 'ciUpperLimit': '0.87', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0084', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.46', 'ciLowerLimit': '0.09', 'ciUpperLimit': '0.82', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0124', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.44', 'ciLowerLimit': '0.07', 'ciUpperLimit': '0.80', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.7565', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.15', 'ciLowerLimit': '-0.23', 'ciUpperLimit': '0.52', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.7158', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.16', 'ciLowerLimit': '-0.22', 'ciUpperLimit': '0.53', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.1368', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.22', 'ciLowerLimit': '-0.52', 'ciUpperLimit': '0.07', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0974', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.28', 'ciLowerLimit': '-0.62', 'ciUpperLimit': '0.05', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0479', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.38', 'ciLowerLimit': '-0.76', 'ciUpperLimit': '-0.00', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.0001', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.84', 'ciLowerLimit': '-1.22', 'ciUpperLimit': '-0.46', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0001', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.83', 'ciLowerLimit': '-1.24', 'ciUpperLimit': '-0.42', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': "The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \\[28 joints\\], swollen joint count (SJC) \\[28 joints\\], patient's global assessment of disease activity \\[visual analog scale: 0=no disease activity to 100=maximum disease activity\\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \\< 2.6.", 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis. Number of participants for whom data were collected is indicated for each time point.'}, {'type': 'SECONDARY', 'title': 'Change in Disease Activity Score From Baseline Based on 28-Joints Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 [ESR])', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '111', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG003', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG004', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG005', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG006', 'title': 'Cohort 2: GDC-0853 Placebo', 'description': 'Participants of Cohort 2 received placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'title': 'Week 1 Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '108', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '106', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-0.35', 'spread': '0.57', 'groupId': 'OG000'}, {'value': '-0.42', 'spread': '0.65', 'groupId': 'OG001'}, {'value': '-0.39', 'spread': '0.68', 'groupId': 'OG002'}, {'value': '-0.34', 'spread': '0.86', 'groupId': 'OG003'}, {'value': '-0.72', 'spread': '0.72', 'groupId': 'OG004'}, {'value': '-0.50', 'spread': '0.73', 'groupId': 'OG005'}, {'value': '-0.31', 'spread': '0.60', 'groupId': 'OG006'}]}]}, {'title': 'Week 2 Day 14', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '109', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '109', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '48', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-0.60', 'spread': '0.89', 'groupId': 'OG000'}, {'value': '-0.69', 'spread': '0.84', 'groupId': 'OG001'}, {'value': '-0.68', 'spread': '0.74', 'groupId': 'OG002'}, {'value': '-0.55', 'spread': '0.92', 'groupId': 'OG003'}, {'value': '-1.02', 'spread': '0.84', 'groupId': 'OG004'}, {'value': '-0.64', 'spread': '0.81', 'groupId': 'OG005'}, {'value': '-0.51', 'spread': '0.73', 'groupId': 'OG006'}]}]}, {'title': 'Week 4 Day 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}, {'value': '104', 'groupId': 'OG001'}, {'value': '106', 'groupId': 'OG002'}, {'value': '108', 'groupId': 'OG003'}, {'value': '109', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '48', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-0.88', 'spread': '0.89', 'groupId': 'OG000'}, {'value': '-0.99', 'spread': '0.98', 'groupId': 'OG001'}, {'value': '-0.97', 'spread': '0.90', 'groupId': 'OG002'}, {'value': '-0.75', 'spread': '1.02', 'groupId': 'OG003'}, {'value': '-1.47', 'spread': '1.02', 'groupId': 'OG004'}, {'value': '-0.85', 'spread': '0.81', 'groupId': 'OG005'}, {'value': '-0.50', 'spread': '0.83', 'groupId': 'OG006'}]}]}, {'title': 'Week 8 Day 56', 'denoms': [{'units': 'Participants', 'counts': [{'value': '37', 'groupId': 'OG000'}, {'value': '100', 'groupId': 'OG001'}, {'value': '103', 'groupId': 'OG002'}, {'value': '102', 'groupId': 'OG003'}, {'value': '108', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '45', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-1.25', 'spread': '0.85', 'groupId': 'OG000'}, {'value': '-1.44', 'spread': '1.14', 'groupId': 'OG001'}, {'value': '-1.40', 'spread': '1.06', 'groupId': 'OG002'}, {'value': '-1.15', 'spread': '1.19', 'groupId': 'OG003'}, {'value': '-1.74', 'spread': '0.98', 'groupId': 'OG004'}, {'value': '-1.35', 'spread': '0.96', 'groupId': 'OG005'}, {'value': '-0.70', 'spread': '0.98', 'groupId': 'OG006'}]}]}, {'title': 'Week 12 Day 84', 'denoms': [{'units': 'Participants', 'counts': [{'value': '37', 'groupId': 'OG000'}, {'value': '97', 'groupId': 'OG001'}, {'value': '97', 'groupId': 'OG002'}, {'value': '102', 'groupId': 'OG003'}, {'value': '108', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '45', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-1.51', 'spread': '1.01', 'groupId': 'OG000'}, {'value': '-1.80', 'spread': '1.25', 'groupId': 'OG001'}, {'value': '-1.80', 'spread': '0.99', 'groupId': 'OG002'}, {'value': '-1.30', 'spread': '1.22', 'groupId': 'OG003'}, {'value': '-1.85', 'spread': '1.06', 'groupId': 'OG004'}, {'value': '-1.65', 'spread': '1.06', 'groupId': 'OG005'}, {'value': '-0.94', 'spread': '10.6', 'groupId': 'OG006'}]}]}], 'analyses': [{'pValue': '0.9193', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.09', 'ciLowerLimit': '-0.41', 'ciUpperLimit': '0.24', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.7062', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.10', 'ciLowerLimit': '-0.33', 'ciUpperLimit': '0.14', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.8542', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.08', 'ciLowerLimit': '-0.31', 'ciUpperLimit': '0.16', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.8095', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.13', 'ciLowerLimit': '-0.51', 'ciUpperLimit': '0.24', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.3862', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.17', 'ciLowerLimit': '-0.44', 'ciUpperLimit': '0.11', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.4328', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.16', 'ciLowerLimit': '-0.43', 'ciUpperLimit': '0.12', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.4915', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.24', 'ciLowerLimit': '-0.68', 'ciUpperLimit': '0.20', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.1441', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.26', 'ciLowerLimit': '-0.58', 'ciUpperLimit': '0.06', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.1890', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.24', 'ciLowerLimit': '-0.56', 'ciUpperLimit': '0.07', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.5566', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.25', 'ciLowerLimit': '-0.74', 'ciUpperLimit': '-0.24', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0920', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.32', 'ciLowerLimit': '-0.68', 'ciUpperLimit': '0.04', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.1391', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.29', 'ciLowerLimit': '-0.65', 'ciUpperLimit': '0.06', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.2873', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.35', 'ciLowerLimit': '-0.86', 'ciUpperLimit': '0.17', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0020', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.54', 'ciLowerLimit': '-0.91', 'ciUpperLimit': '-0.16', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0016', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.54', 'ciLowerLimit': '-0.92', 'ciUpperLimit': '-0.17', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0050', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.31', 'ciLowerLimit': '0.07', 'ciUpperLimit': '0.55', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0020', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.33', 'ciLowerLimit': '0.10', 'ciUpperLimit': '0.57', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0082', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.35', 'ciLowerLimit': '0.07', 'ciUpperLimit': '0.62', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0056', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.35', 'ciLowerLimit': '0.08', 'ciUpperLimit': '0.63', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0004', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.50', 'ciLowerLimit': '0.19', 'ciUpperLimit': '0.82', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0002', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.52', 'ciLowerLimit': '0.21', 'ciUpperLimit': '0.84', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0650', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.34', 'ciLowerLimit': '-0.01', 'ciUpperLimit': '0.69', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0365', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.37', 'ciLowerLimit': '0.02', 'ciUpperLimit': '0.72', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.9338', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.09', 'ciLowerLimit': '-0.28', 'ciUpperLimit': '0.47', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.9520', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.09', 'ciLowerLimit': '-0.29', 'ciUpperLimit': '0.46', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.1496', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.19', 'ciLowerLimit': '-0.45', 'ciUpperLimit': '0.07', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.3936', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.13', 'ciLowerLimit': '-0.43', 'ciUpperLimit': '0.17', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0346', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.35', 'ciLowerLimit': '-0.68', 'ciUpperLimit': '-0.03', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0004', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.68', 'ciLowerLimit': '-1.04', 'ciUpperLimit': '-0.31', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0003', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.73', 'ciLowerLimit': '-1.11', 'ciUpperLimit': '-0.34', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': "The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \\[28 joints\\], swollen joint count (SJC) \\[28 joints\\], patient's global assessment of disease activity \\[visual analog scale: 0=no disease activity to 100=maximum disease activity\\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \\< 2.6.", 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis. Number of participants for whom data were collected is indicated for each time point.'}, {'type': 'SECONDARY', 'title': 'Change in Disease Activity Score From Baseline Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '111', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG003', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG004', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG005', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG006', 'title': 'Cohort 2: GDC-0853 Placebo', 'description': 'Participants of Cohort 2 received placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'title': 'Week 1 Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}, {'value': '103', 'groupId': 'OG001'}, {'value': '103', 'groupId': 'OG002'}, {'value': '104', 'groupId': 'OG003'}, {'value': '103', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '45', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-0.45', 'spread': '0.63', 'groupId': 'OG000'}, {'value': '-0.54', 'spread': '0.72', 'groupId': 'OG001'}, {'value': '-0.52', 'spread': '0.77', 'groupId': 'OG002'}, {'value': '-0.37', 'spread': '0.95', 'groupId': 'OG003'}, {'value': '-0.93', 'spread': '0.76', 'groupId': 'OG004'}, {'value': '-0.65', 'spread': '0.80', 'groupId': 'OG005'}, {'value': '-0.36', 'spread': '0.66', 'groupId': 'OG006'}]}]}, {'title': 'Week 2 Day 14', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}, {'value': '102', 'groupId': 'OG001'}, {'value': '106', 'groupId': 'OG002'}, {'value': '105', 'groupId': 'OG003'}, {'value': '107', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-0.63', 'spread': '0.98', 'groupId': 'OG000'}, {'value': '-0.85', 'spread': '0.85', 'groupId': 'OG001'}, {'value': '-0.84', 'spread': '0.82', 'groupId': 'OG002'}, {'value': '-0.58', 'spread': '1.03', 'groupId': 'OG003'}, {'value': '-1.22', 'spread': '0.94', 'groupId': 'OG004'}, {'value': '-0.81', 'spread': '0.92', 'groupId': 'OG005'}, {'value': '-0.60', 'spread': '0.84', 'groupId': 'OG006'}]}]}, {'title': 'Week 4 Day 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '37', 'groupId': 'OG000'}, {'value': '102', 'groupId': 'OG001'}, {'value': '104', 'groupId': 'OG002'}, {'value': '102', 'groupId': 'OG003'}, {'value': '106', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '48', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-1.00', 'spread': '0.95', 'groupId': 'OG000'}, {'value': '-1.16', 'spread': '1.06', 'groupId': 'OG001'}, {'value': '-1.15', 'spread': '0.98', 'groupId': 'OG002'}, {'value': '-0.79', 'spread': '1.16', 'groupId': 'OG003'}, {'value': '-1.65', 'spread': '1.11', 'groupId': 'OG004'}, {'value': '-1.04', 'spread': '0.95', 'groupId': 'OG005'}, {'value': '-0.61', 'spread': '0.96', 'groupId': 'OG006'}]}]}, {'title': 'Week 8 Day 56', 'denoms': [{'units': 'Participants', 'counts': [{'value': '37', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '100', 'groupId': 'OG002'}, {'value': '99', 'groupId': 'OG003'}, {'value': '105', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '45', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-1.43', 'spread': '0.88', 'groupId': 'OG000'}, {'value': '-1.67', 'spread': '1.25', 'groupId': 'OG001'}, {'value': '-1.63', 'spread': '1.14', 'groupId': 'OG002'}, {'value': '-1.29', 'spread': '1.31', 'groupId': 'OG003'}, {'value': '-2.00', 'spread': '1.06', 'groupId': 'OG004'}, {'value': '-1.54', 'spread': '1.04', 'groupId': 'OG005'}, {'value': '-0.81', 'spread': '1.12', 'groupId': 'OG006'}]}]}, {'title': 'Week 12 Day 84', 'denoms': [{'units': 'Participants', 'counts': [{'value': '36', 'groupId': 'OG000'}, {'value': '94', 'groupId': 'OG001'}, {'value': '95', 'groupId': 'OG002'}, {'value': '99', 'groupId': 'OG003'}, {'value': '106', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '44', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-1.76', 'spread': '1.04', 'groupId': 'OG000'}, {'value': '-2.06', 'spread': '1.36', 'groupId': 'OG001'}, {'value': '-2.05', 'spread': '1.08', 'groupId': 'OG002'}, {'value': '-1.46', 'spread': '1.32', 'groupId': 'OG003'}, {'value': '-2.08', 'spread': '1.14', 'groupId': 'OG004'}, {'value': '-1.89', 'spread': '1.15', 'groupId': 'OG005'}, {'value': '-1.08', 'spread': '1.17', 'groupId': 'OG006'}]}]}], 'analyses': [{'pValue': '0.6083', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.17', 'ciLowerLimit': '-0.53', 'ciUpperLimit': '0.19', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.2672', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.18', 'ciLowerLimit': '-0.44', 'ciUpperLimit': '0.08', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.3158', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.17', 'ciLowerLimit': '-0.43', 'ciUpperLimit': '0.09', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.8495', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.14', 'ciLowerLimit': '-0.55', 'ciUpperLimit': '0.28', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0856', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.28', 'ciLowerLimit': '-0.58', 'ciUpperLimit': '0.03', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.1021', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.27', 'ciLowerLimit': '-0.57', 'ciUpperLimit': '0.04', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.2762', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.33', 'ciLowerLimit': '-0.82', 'ciUpperLimit': '0.15', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0286', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.38', 'ciLowerLimit': '-0.73', 'ciUpperLimit': '-0.03', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0274', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.38', 'ciLowerLimit': '-0.73', 'ciUpperLimit': '-0.03', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.4981', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.28', 'ciLowerLimit': '-0.81', 'ciUpperLimit': '0.24', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0472', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.39', 'ciLowerLimit': '-0.78', 'ciUpperLimit': '-0.00', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0753', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.36', 'ciLowerLimit': '-0.75', 'ciUpperLimit': '0.03', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.1853', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.43', 'ciLowerLimit': '-0.99', 'ciUpperLimit': '0.13', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0009', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.62', 'ciLowerLimit': '-1.03', 'ciUpperLimit': '-0.21', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0008', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.62', 'ciLowerLimit': '-1.03', 'ciUpperLimit': '-0.21', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0005', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.41', 'ciLowerLimit': '0.15', 'ciUpperLimit': '0.67', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0003', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.42', 'ciLowerLimit': '0.16', 'ciUpperLimit': '0.68', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0060', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.39', 'ciLowerLimit': '0.09', 'ciUpperLimit': '0.69', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0039', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.40', 'ciLowerLimit': '0.10', 'ciUpperLimit': '0.70', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0007', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.53', 'ciLowerLimit': '0.18', 'ciUpperLimit': '0.88', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0007', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.53', 'ciLowerLimit': '0.19', 'ciUpperLimit': '0.88', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0450', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.39', 'ciLowerLimit': '0.01', 'ciUpperLimit': '0.77', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0259', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.42', 'ciLowerLimit': '0.04', 'ciUpperLimit': '0.80', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.9881', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.06', 'ciLowerLimit': '-0.34', 'ciUpperLimit': '0.46', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.9891', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.06', 'ciLowerLimit': '-0.34', 'ciUpperLimit': '0.46', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0463', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.29', 'ciLowerLimit': '-0.57', 'ciUpperLimit': '-0.00', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.1867', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.23', 'ciLowerLimit': '-0.56', 'ciUpperLimit': '0.11', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0213', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.44', 'ciLowerLimit': '-0.81', 'ciUpperLimit': '-0.07', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0003', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.78', 'ciLowerLimit': '-1.19', 'ciUpperLimit': '-0.37', 'groupDescription': 'Week 8. Day 56', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0002', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.82', 'ciLowerLimit': '-1.24', 'ciUpperLimit': '-0.40', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': "The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \\[28 joints\\], swollen joint count (SJC) \\[28 joints\\], patient's global assessment of disease activity \\[visual analog scale: 0=no disease activity to 100=maximum disease activity\\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \\< 2.6.", 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis. Number of participants for whom data were collected is indicated for each time point.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With DAS Low Disease Activity', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '111', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG003', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG004', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG005', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG006', 'title': 'Cohort 2: GDC-0853 Placebo', 'description': 'Participants of Cohort 2 received placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'title': 'Week 1 Day 7', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.9', 'groupId': 'OG001', 'lowerLimit': '0.00', 'upperLimit': '2.71'}, {'value': '1.8', 'groupId': 'OG002', 'lowerLimit': '0.00', 'upperLimit': '4.31'}, {'value': '0.0', 'groupId': 'OG003', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '1.8', 'groupId': 'OG004', 'lowerLimit': '0.00', 'upperLimit': '4.28'}, {'value': '2.1', 'groupId': 'OG005', 'lowerLimit': '0.00', 'upperLimit': '6.12'}, {'value': '0.0', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '0.00'}]}]}, {'title': 'Week 2 day 14', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG001', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '1.8', 'groupId': 'OG002', 'lowerLimit': '0.00', 'upperLimit': '4.31'}, {'value': '0.9', 'groupId': 'OG003', 'lowerLimit': '0.00', 'upperLimit': '2.68'}, {'value': '4.5', 'groupId': 'OG004', 'lowerLimit': '0.65', 'upperLimit': '8.36'}, {'value': '2.1', 'groupId': 'OG005', 'lowerLimit': '0.00', 'upperLimit': '6.12'}, {'value': '2.0', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '5.88'}]}]}, {'title': 'Week 4 Day 28', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '1.8', 'groupId': 'OG001', 'lowerLimit': '0.00', 'upperLimit': '4.35'}, {'value': '6.4', 'groupId': 'OG002', 'lowerLimit': '1.80', 'upperLimit': '10.93'}, {'value': '1.8', 'groupId': 'OG003', 'lowerLimit': '0.00', 'upperLimit': '4.31'}, {'value': '11.7', 'groupId': 'OG004', 'lowerLimit': '5.73', 'upperLimit': '17.69'}, {'value': '2.1', 'groupId': 'OG005', 'lowerLimit': '0.00', 'upperLimit': '6.12'}, {'value': '0.0', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '0.00'}]}]}, {'title': 'Week 8 Day 56', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '8.3', 'groupId': 'OG001', 'lowerLimit': '3.09', 'upperLimit': '13.42'}, {'value': '11.8', 'groupId': 'OG002', 'lowerLimit': '5.79', 'upperLimit': '17.85'}, {'value': '3.6', 'groupId': 'OG003', 'lowerLimit': '0.14', 'upperLimit': '7.13'}, {'value': '18.0', 'groupId': 'OG004', 'lowerLimit': '10.87', 'upperLimit': '25.17'}, {'value': '2.1', 'groupId': 'OG005', 'lowerLimit': '0.00', 'upperLimit': '6.12'}, {'value': '2.0', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '5.88'}]}]}, {'title': 'Week 12 Day 84', 'categories': [{'measurements': [{'value': '7.5', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '15.66'}, {'value': '19.3', 'groupId': 'OG001', 'lowerLimit': '11.86', 'upperLimit': '26.67'}, {'value': '14.5', 'groupId': 'OG002', 'lowerLimit': '7.96', 'upperLimit': '21.13'}, {'value': '3.6', 'groupId': 'OG003', 'lowerLimit': '0.14', 'upperLimit': '7.13'}, {'value': '17.1', 'groupId': 'OG004', 'lowerLimit': '10.11', 'upperLimit': '24.12'}, {'value': '14.6', 'groupId': 'OG005', 'lowerLimit': '4.60', 'upperLimit': '24.57'}, {'value': '4.0', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '9.43'}]}]}], 'analyses': [{'pValue': '1.0000', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-6.06', 'ciUpperLimit': '6.06', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.5976', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.91', 'ciLowerLimit': '-2.48', 'ciUpperLimit': '4.30', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.3482', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.82', 'ciLowerLimit': '-1.98', 'ciUpperLimit': '5.62', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.8979', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.40', 'ciLowerLimit': '-6.51', 'ciUpperLimit': '5.71', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.5976', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.91', 'ciLowerLimit': '-4.30', 'ciUpperLimit': '2.48', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.6546', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.91', 'ciLowerLimit': '-3.07', 'ciUpperLimit': '4.89', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.7988', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.80', 'ciLowerLimit': '-6.95', 'ciUpperLimit': '5.35', 'groupDescription': 'Week 4 Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.9975', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.01', 'ciLowerLimit': '-4.35', 'ciUpperLimit': '4.36', 'groupDescription': 'Week 4 Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.1185', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '4.55', 'ciLowerLimit': '-1.16', 'ciUpperLimit': '10.25', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.4765', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-2.40', 'ciLowerLimit': '-9.01', 'ciUpperLimit': '4.21', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.1655', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '4.61', 'ciLowerLimit': '-1.90', 'ciUpperLimit': '11.12', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0234', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '8.18', 'ciLowerLimit': '1.11', 'ciUpperLimit': '15.26', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.5490', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.20', 'ciLowerLimit': '-7.27', 'ciUpperLimit': '13.67', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0003', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '15.62', 'ciLowerLimit': '7.22', 'ciUpperLimit': '24.03', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0044', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '10.91', 'ciLowerLimit': '3.39', 'ciUpperLimit': '18.43', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.6588', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '2.05', 'ciLowerLimit': '-7.07', 'ciUpperLimit': '11.18', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.8853', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.68', 'ciLowerLimit': '-8.62', 'ciUpperLimit': '9.99', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.6564', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '2.05', 'ciLowerLimit': '-7.00', 'ciUpperLimit': '11.11', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.8853', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.68', 'ciLowerLimit': '-8.62', 'ciUpperLimit': '9.99', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0584', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '11.64', 'ciLowerLimit': '-0.41', 'ciUpperLimit': '23.70', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': "The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \\[28 joints\\], swollen joint count (SJC) \\[28 joints\\], patient's global assessment of disease activity \\[visual analog scale: 0=no disease activity to 100=maximum disease activity\\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. LDAS is defined as DAS28 ≤ 3.2", 'unitOfMeasure': 'Percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis. Number of participants for whom data were collected is indicated for each time point'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With DAS Remission', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '111', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG003', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG004', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG005', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG006', 'title': 'Cohort 2: GDC-0853 Placebo', 'description': 'Participants of Cohort 2 received placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'title': 'Week 1 Day 7', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG001', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG002', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG003', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG004', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '2.1', 'groupId': 'OG005', 'lowerLimit': '0.00', 'upperLimit': '6.12'}, {'value': '0.0', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '0.00'}]}]}, {'title': 'Week 2 Day 14', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG001', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.9', 'groupId': 'OG002', 'lowerLimit': '0.00', 'upperLimit': '2.68'}, {'value': '0.0', 'groupId': 'OG003', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.9', 'groupId': 'OG004', 'lowerLimit': '0.00', 'upperLimit': '2.66'}, {'value': '0.00', 'groupId': 'OG005', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '0.00'}]}]}, {'title': 'Week 4 Day 28', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG001', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '1.8', 'groupId': 'OG002', 'lowerLimit': '0.00', 'upperLimit': '4.31'}, {'value': '0.9', 'groupId': 'OG003', 'lowerLimit': '0.00', 'upperLimit': '2.68'}, {'value': '4.5', 'groupId': 'OG004', 'lowerLimit': '0.65', 'upperLimit': '8.36'}, {'value': '0.00', 'groupId': 'OG005', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '0.00'}]}]}, {'title': 'Week 8 Day 56', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '3.7', 'groupId': 'OG001', 'lowerLimit': '0.14', 'upperLimit': '7.20'}, {'value': '4.5', 'groupId': 'OG002', 'lowerLimit': '0.65', 'upperLimit': '8.44'}, {'value': '1.8', 'groupId': 'OG003', 'lowerLimit': '0.00', 'upperLimit': '4.31'}, {'value': '9.0', 'groupId': 'OG004', 'lowerLimit': '3.68', 'upperLimit': '14.34'}, {'value': '0.00', 'groupId': 'OG005', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '0.00'}]}]}, {'title': 'Week 12 Day 84', 'categories': [{'measurements': [{'value': '2.5', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '7.34'}, {'value': '7.3', 'groupId': 'OG001', 'lowerLimit': '2.44', 'upperLimit': '12.24'}, {'value': '8.2', 'groupId': 'OG002', 'lowerLimit': '3.06', 'upperLimit': '13.30'}, {'value': '3.6', 'groupId': 'OG003', 'lowerLimit': '0.14', 'upperLimit': '7.13'}, {'value': '9.0', 'groupId': 'OG004', 'lowerLimit': '3.68', 'upperLimit': '14.34'}, {'value': '4.2', 'groupId': 'OG005', 'lowerLimit': '0.00', 'upperLimit': '9.82'}, {'value': '4.0', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '9.43'}]}]}], 'analyses': [{'pValue': '1.0000', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-6.06', 'ciUpperLimit': '6.06', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-2.92', 'ciUpperLimit': '2.92', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-2.91', 'ciUpperLimit': '2.91', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-6.06', 'ciUpperLimit': '6.06', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-2.92', 'ciUpperLimit': '2.92', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.5976', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.91', 'ciLowerLimit': '-2.47', 'ciUpperLimit': '4.28', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.8979', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.40', 'ciLowerLimit': '-6.51', 'ciUpperLimit': '5.71', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.5976', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.91', 'ciLowerLimit': '-4.30', 'ciUpperLimit': '2.48', 'groupDescription': 'Week 4 Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.6669', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.91', 'ciLowerLimit': '-3.23', 'ciUpperLimit': '5.05', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.6309', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.60', 'ciLowerLimit': '-8.13', 'ciUpperLimit': '4.93', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.4473', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.83', 'ciLowerLimit': '-2.90', 'ciUpperLimit': '6.56', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.3021', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '2.73', 'ciLowerLimit': '-2.45', 'ciUpperLimit': '7.91', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.7134', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.60', 'ciLowerLimit': '-10.14', 'ciUpperLimit': '6.94', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.2635', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.70', 'ciLowerLimit': '-2.79', 'ciUpperLimit': '10.19', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.1749', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '4.55', 'ciLowerLimit': '-2.02', 'ciUpperLimit': '11.11', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.6588', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '2.05', 'ciLowerLimit': '-7.07', 'ciUpperLimit': '11.18', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-8.31', 'ciUpperLimit': '8.31', 'groupDescription': 'Week 2 Day 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-8.31', 'ciUpperLimit': '8.31', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-8.31', 'ciUpperLimit': '8.31', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.7848', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.37', 'ciLowerLimit': '-8.46', 'ciUpperLimit': '11.20', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': "The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \\[28 joints\\], swollen joint count (SJC) \\[28 joints\\], patient's global assessment of disease activity \\[visual analog scale: 0=no disease activity to 100=maximum disease activity\\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \\< 2.6", 'unitOfMeasure': 'Percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis. Number of participants for whom data were collected is indicated for each time point.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Meeting the Boolean-based Remission Criteria', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '111', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG003', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG004', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG005', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG006', 'title': 'Cohort 2: GDC-0853 Placebo', 'description': 'Participants of Cohort 2 received placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'title': 'Week 1 Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}, {'value': '107', 'groupId': 'OG001'}, {'value': '108', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '107', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.9', 'groupId': 'OG001', 'lowerLimit': '0.00', 'upperLimit': '2.76'}, {'value': '0.0', 'groupId': 'OG002', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG003', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG004', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG005', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '0.00'}]}]}, {'title': 'Week 2 Day 14', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '107', 'groupId': 'OG001'}, {'value': '109', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '109', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '49', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG001', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG002', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG003', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG004', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG005', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '0.00'}]}]}, {'title': 'Week 4 Day 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '107', 'groupId': 'OG002'}, {'value': '108', 'groupId': 'OG003'}, {'value': '109', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '48', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '1.0', 'groupId': 'OG001', 'lowerLimit': '0.00', 'upperLimit': '2.81'}, {'value': '0.0', 'groupId': 'OG002', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.9', 'groupId': 'OG003', 'lowerLimit': '0.00', 'upperLimit': '2.73'}, {'value': '2.8', 'groupId': 'OG004', 'lowerLimit': '0.00', 'upperLimit': '5.82'}, {'value': '2.1', 'groupId': 'OG005', 'lowerLimit': '0.00', 'upperLimit': '6.25'}, {'value': '0.0', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '0.00'}]}]}, {'title': 'Week 8 Day 56', 'denoms': [{'units': 'Participants', 'counts': [{'value': '37', 'groupId': 'OG000'}, {'value': '101', 'groupId': 'OG001'}, {'value': '104', 'groupId': 'OG002'}, {'value': '103', 'groupId': 'OG003'}, {'value': '109', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '45', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '2.0', 'groupId': 'OG001', 'lowerLimit': '0.00', 'upperLimit': '4.70'}, {'value': '1.90', 'groupId': 'OG002', 'lowerLimit': '0.00', 'upperLimit': '4.56'}, {'value': '1.0', 'groupId': 'OG003', 'lowerLimit': '0.00', 'upperLimit': '2.86'}, {'value': '3.7', 'groupId': 'OG004', 'lowerLimit': '0.14', 'upperLimit': '7.20'}, {'value': '0.0', 'groupId': 'OG005', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '0.00'}]}]}, {'title': 'Week 12 Day 84', 'denoms': [{'units': 'Participants', 'counts': [{'value': '37', 'groupId': 'OG000'}, {'value': '98', 'groupId': 'OG001'}, {'value': '97', 'groupId': 'OG002'}, {'value': '102', 'groupId': 'OG003'}, {'value': '108', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '45', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '2.0', 'groupId': 'OG001', 'lowerLimit': '0.00', 'upperLimit': '4.84'}, {'value': '4.1', 'groupId': 'OG002', 'lowerLimit': '0.17', 'upperLimit': '8.08'}, {'value': '1.0', 'groupId': 'OG003', 'lowerLimit': '0.00', 'upperLimit': '2.89'}, {'value': '6.5', 'groupId': 'OG004', 'lowerLimit': '1.84', 'upperLimit': '11.12'}, {'value': '8.5', 'groupId': 'OG005', 'lowerLimit': '0.53', 'upperLimit': '16.49'}, {'value': '0.0', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '6.53'}]}]}], 'analyses': [{'pValue': '1.0000', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-6.28', 'ciUpperLimit': '6.28', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.5941', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.93', 'ciLowerLimit': '-2.50', 'ciUpperLimit': '4.37', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-2.93', 'ciUpperLimit': '2.93', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-6.17', 'ciUpperLimit': '6.17', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-2.95', 'ciUpperLimit': '2.95', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-2.92', 'ciUpperLimit': '2.92', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.8929', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.43', 'ciLowerLimit': '-6.62', 'ciUpperLimit': '5.77', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.9424', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.13', 'ciLowerLimit': '-3.78', 'ciUpperLimit': '3.51', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.5927', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.94', 'ciLowerLimit': '-4.40', 'ciUpperLimit': '2.51', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.8788', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.46', 'ciLowerLimit': '-6.31', 'ciUpperLimit': '5.40', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.6876', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.87', 'ciLowerLimit': '-3.36', 'ciUpperLimit': '5.09', 'groupDescription': 'Week 8 Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.6656', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.97', 'ciLowerLimit': '-3.42', 'ciUpperLimit': '5.35', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.8787', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.46', 'ciLowerLimit': '-6.34', 'ciUpperLimit': '5.42', 'groupDescription': 'Week 12 Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.7101', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.74', 'ciLowerLimit': '-3.17', 'ciUpperLimit': '4.66', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.2425', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.20', 'ciLowerLimit': '-2.16', 'ciUpperLimit': '8.55', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-8.68', 'ciUpperLimit': '8.68', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-8.39', 'ciUpperLimit': '8.39', 'groupDescription': 'Week 2 Day 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.6658', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '2.03', 'ciLowerLimit': '-7.17', 'ciUpperLimit': '11.22', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-8.77', 'ciUpperLimit': '8.77', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.2457', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '6.57', 'ciLowerLimit': '-4.52', 'ciUpperLimit': '17.66', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': 'Boolean Remission is defined as Tender joint count less than 1, Swollen joint count less than 1, CRP less than 1 mg/dL, patient global assessment less than 1 (on 0 to 10 VAS scale).', 'unitOfMeasure': 'Percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis. Number of participants for whom data were collected is indicated for each time point.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Clinical Disease Activity Index (CDAI)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '111', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG003', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG004', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG005', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG006', 'title': 'Cohort 2: GDC-0853 Placebo', 'description': 'Participants of Cohort 2 received placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'title': 'Week 1 Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '103', 'groupId': 'OG002'}, {'value': '104', 'groupId': 'OG003'}, {'value': '104', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '45', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-5.45', 'spread': '7.69', 'groupId': 'OG000'}, {'value': '-6.70', 'spread': '8.26', 'groupId': 'OG001'}, {'value': '-7.40', 'spread': '9.97', 'groupId': 'OG002'}, {'value': '-4.71', 'spread': '12.91', 'groupId': 'OG003'}, {'value': '-9.64', 'spread': '8.93', 'groupId': 'OG004'}, {'value': '-8.61', 'spread': '10.67', 'groupId': 'OG005'}, {'value': '-5.26', 'spread': '9.79', 'groupId': 'OG006'}]}]}, {'title': 'Week 2 Day 14', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}, {'value': '103', 'groupId': 'OG001'}, {'value': '106', 'groupId': 'OG002'}, {'value': '105', 'groupId': 'OG003'}, {'value': '107', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-6.85', 'spread': '11.10', 'groupId': 'OG000'}, {'value': '-10.33', 'spread': '10.45', 'groupId': 'OG001'}, {'value': '-11.33', 'spread': '10.47', 'groupId': 'OG002'}, {'value': '-7.44', 'spread': '13.39', 'groupId': 'OG003'}, {'value': '-13.44', 'spread': '10.52', 'groupId': 'OG004'}, {'value': '-9.64', 'spread': '12.17', 'groupId': 'OG005'}, {'value': '-7.70', 'spread': '10.64', 'groupId': 'OG006'}]}]}, {'title': 'Week 4 Day 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '37', 'groupId': 'OG000'}, {'value': '100', 'groupId': 'OG001'}, {'value': '100', 'groupId': 'OG002'}, {'value': '99', 'groupId': 'OG003'}, {'value': '105', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '48', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-10.36', 'spread': '10.88', 'groupId': 'OG000'}, {'value': '-13.84', 'spread': '12.11', 'groupId': 'OG001'}, {'value': '-13.78', 'spread': '11.46', 'groupId': 'OG002'}, {'value': '-9.43', 'spread': '14.77', 'groupId': 'OG003'}, {'value': '-17.74', 'spread': '10.84', 'groupId': 'OG004'}, {'value': '-11.83', 'spread': '11.08', 'groupId': 'OG005'}, {'value': '-7.49', 'spread': '11.46', 'groupId': 'OG006'}]}]}, {'title': 'Week 8 Day 56', 'denoms': [{'units': 'Participants', 'counts': [{'value': '37', 'groupId': 'OG000'}, {'value': '100', 'groupId': 'OG001'}, {'value': '100', 'groupId': 'OG002'}, {'value': '99', 'groupId': 'OG003'}, {'value': '105', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '44', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-14.76', 'spread': '10.04', 'groupId': 'OG000'}, {'value': '-18.61', 'spread': '13.48', 'groupId': 'OG001'}, {'value': '-18.10', 'spread': '12.99', 'groupId': 'OG002'}, {'value': '-15.49', 'spread': '15.74', 'groupId': 'OG003'}, {'value': '-21.36', 'spread': '11.69', 'groupId': 'OG004'}, {'value': '-17.38', 'spread': '12.39', 'groupId': 'OG005'}, {'value': '-7.57', 'spread': '10.51', 'groupId': 'OG006'}]}]}, {'title': 'Week 12 Day 84', 'denoms': [{'units': 'Participants', 'counts': [{'value': '36', 'groupId': 'OG000'}, {'value': '95', 'groupId': 'OG001'}, {'value': '94', 'groupId': 'OG002'}, {'value': '99', 'groupId': 'OG003'}, {'value': '105', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '44', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-16.99', 'spread': '11.21', 'groupId': 'OG000'}, {'value': '-22.05', 'spread': '12.19', 'groupId': 'OG001'}, {'value': '-22.10', 'spread': '11.83', 'groupId': 'OG002'}, {'value': '-17.02', 'spread': '16.24', 'groupId': 'OG003'}, {'value': '-22.22', 'spread': '11.76', 'groupId': 'OG004'}, {'value': '-20.42', 'spread': '13.20', 'groupId': 'OG005'}, {'value': '-12.23', 'spread': '12.06', 'groupId': 'OG006'}]}]}], 'analyses': [{'pValue': '0.4960', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-2.36', 'ciLowerLimit': '-6.73', 'ciUpperLimit': '2.02', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.2736', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-2.18', 'ciLowerLimit': '-5.34', 'ciUpperLimit': '0.98', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0608', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-3.08', 'ciLowerLimit': '-6.26', 'ciUpperLimit': '0.10', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.9237', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.25', 'ciLowerLimit': '-6.02', 'ciUpperLimit': '3.52', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0893', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-3.14', 'ciLowerLimit': '-6.60', 'ciUpperLimit': '0.33', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0138', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-4.07', 'ciLowerLimit': '-7.51', 'ciUpperLimit': '-0.63', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.3358', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-3.22', 'ciLowerLimit': '-8.24', 'ciUpperLimit': '1.80', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0078', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-4.57', 'ciLowerLimit': '-8.20', 'ciUpperLimit': '-0.94', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0059', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-4.68', 'ciLowerLimit': '-8.30', 'ciUpperLimit': '-1.06', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.6503', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-2.29', 'ciLowerLimit': '-7.39', 'ciUpperLimit': '2.80', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.1282', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-3.12', 'ciLowerLimit': '-6.84', 'ciUpperLimit': '0.59', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.1675', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-2.94', 'ciLowerLimit': '-6.65', 'ciUpperLimit': '0.78', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.4220', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-2.94', 'ciLowerLimit': '-7.96', 'ciUpperLimit': '2.09', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0027', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-5.10', 'ciLowerLimit': '-8.77', 'ciUpperLimit': '-1.42', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0011', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-5.47', 'ciLowerLimit': '-9.15', 'ciUpperLimit': '-1.78', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0455', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.21', 'ciLowerLimit': '0.05', 'ciUpperLimit': '6.37', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.2309', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '2.31', 'ciLowerLimit': '-0.87', 'ciUpperLimit': '5.48', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0698', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.27', 'ciLowerLimit': '-0.18', 'ciUpperLimit': '6.72', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.2851', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '2.33', 'ciLowerLimit': '-1.09', 'ciUpperLimit': '5.76', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0131', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '4.29', 'ciLowerLimit': '0.69', 'ciUpperLimit': '7.90', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0161', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '4.18', 'ciLowerLimit': '0.59', 'ciUpperLimit': '7.78', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0360', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.85', 'ciLowerLimit': '0.18', 'ciUpperLimit': '7.51', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0252', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '4.04', 'ciLowerLimit': '0.37', 'ciUpperLimit': '7.70', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.9032', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.03', 'ciLowerLimit': '-2.59', 'ciUpperLimit': '4.66', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.9791', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.66', 'ciLowerLimit': '-2.97', 'ciUpperLimit': '4.30', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0927', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-3.22', 'ciLowerLimit': '-6.98', 'ciUpperLimit': '0.54', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.3202', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-2.12', 'ciLowerLimit': '-6.33', 'ciUpperLimit': '2.09', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0476', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-4.20', 'ciLowerLimit': '-8.36', 'ciUpperLimit': '-0.04', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.0001', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-9.93', 'ciLowerLimit': '-14.31', 'ciUpperLimit': '-5.55', 'groupDescription': 'Week 8, Day 54', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0003', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-8.23', 'ciLowerLimit': '-12.56', 'ciUpperLimit': '-3.90', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Days 7, 14, 28, 56 and 84', 'description': 'CDAI was derived as the sum of the following: tender joint count (TJC), swollen joint count (SJC), participant global assessment (PGA) of disease activity, and physician assessment of disease activity. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA and physician assessment of disease activity were scored 0-100 millimeters (mm) and rounded to the nearest centimeter (cm) on a visual analog scale (VAS), where higher scores indicate greater perceived disease activity. The total CDAI score range was 0-76, where higher scores indicate increased disease activity. Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest. Negative values indicate improvement/reduction in RA disease activity.', 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis. Number of participants for whom data were collected is indicated for each time point.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Meeting the CDAI-based Remission Criteria', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '111', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG003', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG004', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG005', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG006', 'title': 'Cohort 2: GDC-0853 Placebo', 'description': 'Participants of Cohort 2 received placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'title': 'Week 1 Day 7', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.9', 'groupId': 'OG001', 'lowerLimit': '0.00', 'upperLimit': '2.71'}, {'value': '0.9', 'groupId': 'OG002', 'lowerLimit': '0.00', 'upperLimit': '2.68'}, {'value': '0.0', 'groupId': 'OG003', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG004', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG005', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '0.00'}]}]}, {'title': 'Week 2 Day 14', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG001', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG002', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG003', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '1.8', 'groupId': 'OG004', 'lowerLimit': '0.00', 'upperLimit': '4.28'}, {'value': '0.0', 'groupId': 'OG005', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.0', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '0.00'}]}]}, {'title': 'Week 4 Day 28', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.9', 'groupId': 'OG001', 'lowerLimit': '0.00', 'upperLimit': '2.71'}, {'value': '0.9', 'groupId': 'OG002', 'lowerLimit': '0.00', 'upperLimit': '2.68'}, {'value': '0.0', 'groupId': 'OG003', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '4.5', 'groupId': 'OG004', 'lowerLimit': '0.65', 'upperLimit': '8.36'}, {'value': '2.1', 'groupId': 'OG005', 'lowerLimit': '0.00', 'upperLimit': '6.12'}, {'value': '0.0', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '0.00'}]}]}, {'title': 'Week 8 Day 56', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '2.8', 'groupId': 'OG001', 'lowerLimit': '0.00', 'upperLimit': '5.82'}, {'value': '5.5', 'groupId': 'OG002', 'lowerLimit': '1.21', 'upperLimit': '9.70'}, {'value': '0.00', 'groupId': 'OG003', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '7.2', 'groupId': 'OG004', 'lowerLimit': '2.40', 'upperLimit': '12.02'}, {'value': '4.2', 'groupId': 'OG005', 'lowerLimit': '0.00', 'upperLimit': '9.82'}, {'value': '0.0', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '0.00'}]}]}, {'title': 'Week 12 Day 84', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '5.5', 'groupId': 'OG001', 'lowerLimit': '1.22', 'upperLimit': '9.79'}, {'value': '6.4', 'groupId': 'OG002', 'lowerLimit': '1.80', 'upperLimit': '10.93'}, {'value': '0.9', 'groupId': 'OG003', 'lowerLimit': '0.00', 'upperLimit': '2.68'}, {'value': '9.9', 'groupId': 'OG004', 'lowerLimit': '4.35', 'upperLimit': '15.47'}, {'value': '6.3', 'groupId': 'OG005', 'lowerLimit': '0.00', 'upperLimit': '13.10'}, {'value': '6.0', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '12.58'}]}]}], 'analyses': [{'pValue': '1.0000', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-6.06', 'ciUpperLimit': '6.06', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.5976', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.91', 'ciLowerLimit': '-2.48', 'ciUpperLimit': '4.30', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.5976', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.91', 'ciLowerLimit': '-2.47', 'ciUpperLimit': '4.28', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-6.06', 'ciUpperLimit': '6.06', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-2.92', 'ciUpperLimit': '2.92', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-2.91', 'ciUpperLimit': '2.91', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-6.06', 'ciUpperLimit': '6.06', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.5726', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.91', 'ciLowerLimit': '-2.26', 'ciUpperLimit': '4.09', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.5976', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.91', 'ciLowerLimit': '-2.47', 'ciUpperLimit': '4.28', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-6.06', 'ciUpperLimit': '6.06', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.1446', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '2.74', 'ciLowerLimit': '-0.94', 'ciUpperLimit': '6.42', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0286', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '5.45', 'ciLowerLimit': '0.57', 'ciUpperLimit': '10.34', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.8979', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.40', 'ciLowerLimit': '-6.51', 'ciUpperLimit': '5.71', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0708', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '4.57', 'ciLowerLimit': '-0.39', 'ciUpperLimit': '9.52', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0478', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '5.45', 'ciLowerLimit': '0.05', 'ciUpperLimit': '10.86', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-8.31', 'ciUpperLimit': '8.31', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-8.31', 'ciUpperLimit': '8.31', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.6564', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '2.05', 'ciLowerLimit': '-7.00', 'ciUpperLimit': '11.11', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.3838', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '4.11', 'ciLowerLimit': '-5.14', 'ciUpperLimit': '13.36', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.9009', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.68', 'ciLowerLimit': '-10.10', 'ciUpperLimit': '11.47', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': "Clinical Disease Activity Index is defined as CDAI= : SJC(28) + TJC(28) + PGA + MDG where TJC and SJC are the tender and swollen joint counts from 28 joints, PGA is the patient's global assessment of disease activity (on a 0-10 scale) and MDG is physician global assessment of disease activity (on a 0-10 scale). The cutoff value for CDAI remission is \\<=2.8.", 'unitOfMeasure': 'Percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis. Number of participants for whom data were collected is indicated for each time point.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Simplified Disease Activity Index (SDAI)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '111', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG003', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG004', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG005', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG006', 'title': 'Cohort 2: GDC-0853 Placebo', 'description': 'Participants of Cohort 2 received placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'title': 'Week 1 Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '37', 'groupId': 'OG000'}, {'value': '104', 'groupId': 'OG001'}, {'value': '102', 'groupId': 'OG002'}, {'value': '103', 'groupId': 'OG003'}, {'value': '104', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '45', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-5.36', 'spread': '7.86', 'groupId': 'OG000'}, {'value': '-6.48', 'spread': '8.87', 'groupId': 'OG001'}, {'value': '-6.99', 'spread': '10.49', 'groupId': 'OG002'}, {'value': '-4.75', 'spread': '13.25', 'groupId': 'OG003'}, {'value': '-10.86', 'spread': '9.33', 'groupId': 'OG004'}, {'value': '-8.73', 'spread': '11.21', 'groupId': 'OG005'}, {'value': '-5.37', 'spread': '9.49', 'groupId': 'OG006'}]}]}, {'title': 'Week 2 Day 14', 'denoms': [{'units': 'Participants', 'counts': [{'value': '37', 'groupId': 'OG000'}, {'value': '103', 'groupId': 'OG001'}, {'value': '105', 'groupId': 'OG002'}, {'value': '105', 'groupId': 'OG003'}, {'value': '107', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '46', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-6.50', 'spread': '10.54', 'groupId': 'OG000'}, {'value': '-10.46', 'spread': '10.97', 'groupId': 'OG001'}, {'value': '-11.44', 'spread': '10.85', 'groupId': 'OG002'}, {'value': '-7.54', 'spread': '13.74', 'groupId': 'OG003'}, {'value': '-14.39', 'spread': '10.99', 'groupId': 'OG004'}, {'value': '-9.84', 'spread': '12.29', 'groupId': 'OG005'}, {'value': '-8.13', 'spread': '11.01', 'groupId': 'OG006'}]}]}, {'title': 'Week 4 Day 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '36', 'groupId': 'OG000'}, {'value': '101', 'groupId': 'OG001'}, {'value': '103', 'groupId': 'OG002'}, {'value': '99', 'groupId': 'OG003'}, {'value': '105', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '48', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-10.53', 'spread': '11.03', 'groupId': 'OG000'}, {'value': '-14.47', 'spread': '12.41', 'groupId': 'OG001'}, {'value': '-14.21', 'spread': '12.20', 'groupId': 'OG002'}, {'value': '-8.92', 'spread': '15.17', 'groupId': 'OG003'}, {'value': '-18.87', 'spread': '11.20', 'groupId': 'OG004'}, {'value': '-12.13', 'spread': '11.13', 'groupId': 'OG005'}, {'value': '-7.74', 'spread': '12.02', 'groupId': 'OG006'}]}]}, {'title': 'Week 8 Day 56', 'denoms': [{'units': 'Participants', 'counts': [{'value': '36', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '100', 'groupId': 'OG002'}, {'value': '97', 'groupId': 'OG003'}, {'value': '103', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '44', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-15.25', 'spread': '10.41', 'groupId': 'OG000'}, {'value': '-18.95', 'spread': '13.80', 'groupId': 'OG001'}, {'value': '-18.97', 'spread': '13.91', 'groupId': 'OG002'}, {'value': '-15.74', 'spread': '16.18', 'groupId': 'OG003'}, {'value': '-22.62', 'spread': '11.97', 'groupId': 'OG004'}, {'value': '-18.57', 'spread': '12.80', 'groupId': 'OG005'}, {'value': '-7.82', 'spread': '11.20', 'groupId': 'OG006'}]}]}, {'title': 'Week 12 Day 84', 'denoms': [{'units': 'Participants', 'counts': [{'value': '36', 'groupId': 'OG000'}, {'value': '94', 'groupId': 'OG001'}, {'value': '94', 'groupId': 'OG002'}, {'value': '99', 'groupId': 'OG003'}, {'value': '103', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-17.54', 'spread': '11.36', 'groupId': 'OG000'}, {'value': '-22.89', 'spread': '12.52', 'groupId': 'OG001'}, {'value': '-23.24', 'spread': '12.50', 'groupId': 'OG002'}, {'value': '-17.47', 'spread': '16.70', 'groupId': 'OG003'}, {'value': '-23.33', 'spread': '11.97', 'groupId': 'OG004'}, {'value': '-21.97', 'spread': '13.78', 'groupId': 'OG005'}, {'value': '-12.92', 'spread': '12.61', 'groupId': 'OG006'}]}]}], 'analyses': [{'pValue': '0.5455', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-2.36', 'ciLowerLimit': '-7.00', 'ciUpperLimit': '2.27', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.4114', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.97', 'ciLowerLimit': '-5.30', 'ciUpperLimit': '1.36', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.1739', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-2.62', 'ciLowerLimit': '-5.97', 'ciUpperLimit': '0.72', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.9761', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.94', 'ciLowerLimit': '-5.93', 'ciUpperLimit': '4.06', 'groupDescription': 'Week 2, Week 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0998', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-3.18', 'ciLowerLimit': '-6.78', 'ciUpperLimit': '0.41', 'groupDescription': 'Week 2, Week 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0239', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-3.97', 'ciLowerLimit': '-7.54', 'ciUpperLimit': '-0.39', 'groupDescription': 'Week 2, Week 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.2018', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-3.98', 'ciLowerLimit': '-9.25', 'ciUpperLimit': '1.30', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0011', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-5.67', 'ciLowerLimit': '-9.48', 'ciUpperLimit': '-1.87', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0026', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-5.27', 'ciLowerLimit': '-9.06', 'ciUpperLimit': '-1.48', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.6336', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-2.47', 'ciLowerLimit': '-7.84', 'ciUpperLimit': '2.90', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0950', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-3.49', 'ciLowerLimit': '-7.38', 'ciUpperLimit': '0.41', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.1451', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-3.18', 'ciLowerLimit': '-7.06', 'ciUpperLimit': '0.71', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.3434', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-3.28', 'ciLowerLimit': '-8.43', 'ciUpperLimit': '1.87', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0016', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-5.45', 'ciLowerLimit': '-9.23', 'ciUpperLimit': '-1.68', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0006', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-5.88', 'ciLowerLimit': '-9.65', 'ciUpperLimit': '-2.10', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0025', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '4.64', 'ciLowerLimit': '1.31', 'ciUpperLimit': '7.96', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0129', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.98', 'ciLowerLimit': '0.64', 'ciUpperLimit': '7.32', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0206', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '4.04', 'ciLowerLimit': '0.46', 'ciUpperLimit': '7.62', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0841', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.26', 'ciLowerLimit': '-0.30', 'ciUpperLimit': '6.82', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0088', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '4.67', 'ciLowerLimit': '0.91', 'ciUpperLimit': '8.42', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0034', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '5.07', 'ciLowerLimit': '1.34', 'ciUpperLimit': '8.81', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0138', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '4.55', 'ciLowerLimit': '0.71', 'ciUpperLimit': '8.39', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0073', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '4.85', 'ciLowerLimit': '1.02', 'ciUpperLimit': '8.69', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.8284', 'groupIds': ['OG001', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.29', 'ciLowerLimit': '-2.46', 'ciUpperLimit': '5.03', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.9525', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.86', 'ciLowerLimit': '-2.88', 'ciUpperLimit': '4.60', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0856', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-3.22', 'ciLowerLimit': '-6.91', 'ciUpperLimit': '0.46', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.3374', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-2.08', 'ciLowerLimit': '-6.36', 'ciUpperLimit': '2.20', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0534', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-4.24', 'ciLowerLimit': '-8.53', 'ciUpperLimit': '0.06', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.0001', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-10.8', 'ciLowerLimit': '-15.33', 'ciUpperLimit': '-6.32', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.0001', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-9.22', 'ciLowerLimit': '-13.63', 'ciUpperLimit': '-4.81', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Days 7, 14, 28, 56 and 84', 'description': 'Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\\< 3.3 indicates disease remission, \\> 3.4 to 11 indicates low disease activity, \\> 11 to 26 indicates moderate disease activity, and \\> 26 indicates high disease activity', 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis. Number of participants for whom data were collected is indicated for each time point.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Meeting the SDAI-based Remission Criteria', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '111', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG003', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG004', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG005', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG006', 'title': 'Cohort 2: GDC-0853 Placebo', 'description': 'Participants of Cohort 2 received placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'title': 'Week 1 Day 7', 'categories': [{'measurements': [{'value': '0.00', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.9', 'groupId': 'OG001', 'lowerLimit': '0.00', 'upperLimit': '2.71'}, {'value': '0.00', 'groupId': 'OG002', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.00', 'groupId': 'OG003', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.00', 'groupId': 'OG004', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.00', 'groupId': 'OG005', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.00', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '0.00'}]}]}, {'title': 'Week 2 Day 14', 'categories': [{'measurements': [{'value': '0.00', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.00', 'groupId': 'OG001', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.00', 'groupId': 'OG002', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.00', 'groupId': 'OG003', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '1.8', 'groupId': 'OG004', 'lowerLimit': '0.00', 'upperLimit': '4.28'}, {'value': '0.00', 'groupId': 'OG005', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.00', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '0.00'}]}]}, {'title': 'Week 4 Day 28', 'categories': [{'measurements': [{'value': '0.00', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.9', 'groupId': 'OG001', 'lowerLimit': '0.00', 'upperLimit': '2.71'}, {'value': '0.9', 'groupId': 'OG002', 'lowerLimit': '0.00', 'upperLimit': '2.68'}, {'value': '0.00', 'groupId': 'OG003', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '4.5', 'groupId': 'OG004', 'lowerLimit': '0.65', 'upperLimit': '8.36'}, {'value': '2.1', 'groupId': 'OG005', 'lowerLimit': '0.00', 'upperLimit': '6.12'}, {'value': '0.00', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '0.00'}]}]}, {'title': 'Week 8 Day 56', 'categories': [{'measurements': [{'value': '0.00', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '2.8', 'groupId': 'OG001', 'lowerLimit': '0.00', 'upperLimit': '5.82'}, {'value': '3.6', 'groupId': 'OG002', 'lowerLimit': '0.14', 'upperLimit': '7.13'}, {'value': '0.00', 'groupId': 'OG003', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '6.3', 'groupId': 'OG004', 'lowerLimit': '1.78', 'upperLimit': '10.83'}, {'value': '0.00', 'groupId': 'OG005', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.00', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '0.00'}]}]}, {'title': 'Week 12 Day 84', 'categories': [{'measurements': [{'value': '0.00', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '4.6', 'groupId': 'OG001', 'lowerLimit': '0.66', 'upperLimit': '8.51'}, {'value': '6.4', 'groupId': 'OG002', 'lowerLimit': '1.80', 'upperLimit': '10.93'}, {'value': '0.9', 'groupId': 'OG003', 'lowerLimit': '0.00', 'upperLimit': '2.68'}, {'value': '9.0', 'groupId': 'OG004', 'lowerLimit': '3.68', 'upperLimit': '14.34'}, {'value': '6.3', 'groupId': 'OG005', 'lowerLimit': '0.00', 'upperLimit': '13.10'}, {'value': '6.0', 'groupId': 'OG006', 'lowerLimit': '0.00', 'upperLimit': '12.58'}]}]}], 'analyses': [{'pValue': '1.0000', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-6.06', 'ciUpperLimit': '6.06', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.5976', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.91', 'ciLowerLimit': '-2.48', 'ciUpperLimit': '4.30', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-2.91', 'ciUpperLimit': '2.91', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-6.06', 'ciUpperLimit': '6.06', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-2.92', 'ciUpperLimit': '2.92', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-2.91', 'ciUpperLimit': '2.91', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-6.06', 'ciUpperLimit': '6.06', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.5726', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.91', 'ciLowerLimit': '-2.26', 'ciUpperLimit': '4.09', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.5976', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.91', 'ciLowerLimit': '-2.47', 'ciUpperLimit': '4.28', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-6.06', 'ciUpperLimit': '6.06', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.1446', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '2.74', 'ciLowerLimit': '-0.94', 'ciUpperLimit': '6.42', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.1050', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.64', 'ciLowerLimit': '-0.76', 'ciUpperLimit': '8.03', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.8979', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.40', 'ciLowerLimit': '-6.51', 'ciUpperLimit': '5.71', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.1270', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.65', 'ciLowerLimit': '-1.04', 'ciUpperLimit': '8.35', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0501', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '5.45', 'ciLowerLimit': '-0.00', 'ciUpperLimit': '10.91', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-8.31', 'ciUpperLimit': '8.31', 'groupDescription': 'Week 1, Day 7', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-8.31', 'ciUpperLimit': '8.31', 'groupDescription': 'Week 2, Day 14', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.6564', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '2.05', 'ciLowerLimit': '-7.00', 'ciUpperLimit': '11.11', 'groupDescription': 'Week 4, Day 28', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '1.0000', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-8.31', 'ciUpperLimit': '8.31', 'groupDescription': 'Week 8, Day 56', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.9051', 'groupIds': ['OG005', 'OG006'], 'paramType': 'Adjusted Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.68', 'ciLowerLimit': '-10.58', 'ciUpperLimit': '11.95', 'groupDescription': 'Week 12, Day 84', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': 'The SDAI was the numerical sum of five outcome parameter: SJC and TJC (based on a 28-joint assessment), PGA and MDG (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. The SDAI =\\< 3.3 indicates disease remission', 'unitOfMeasure': 'Percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis. Number of participants for whom data were collected is indicated for each time point.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Version 2.0 (V2) Scores for Physical and Mental Components', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '111', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG003', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG004', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG005', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG006', 'title': 'Cohort 2: GDC-0853 Placebo', 'description': 'Participants of Cohort 2 received placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'title': 'Physical component score change: baseline-week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '35', 'groupId': 'OG000'}, {'value': '98', 'groupId': 'OG001'}, {'value': '100', 'groupId': 'OG002'}, {'value': '99', 'groupId': 'OG003'}, {'value': '106', 'groupId': 'OG004'}, {'value': '45', 'groupId': 'OG005'}, {'value': '44', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '5.57', 'spread': '5.98', 'groupId': 'OG000'}, {'value': '5.71', 'spread': '6.85', 'groupId': 'OG001'}, {'value': '6.59', 'spread': '7.54', 'groupId': 'OG002'}, {'value': '3.54', 'spread': '6.81', 'groupId': 'OG003'}, {'value': '6.41', 'spread': '6.43', 'groupId': 'OG004'}, {'value': '5.35', 'spread': '7.48', 'groupId': 'OG005'}, {'value': '1.75', 'spread': '6.39', 'groupId': 'OG006'}]}]}, {'title': 'Mental component score change: baseline-week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '36', 'groupId': 'OG000'}, {'value': '98', 'groupId': 'OG001'}, {'value': '101', 'groupId': 'OG002'}, {'value': '99', 'groupId': 'OG003'}, {'value': '106', 'groupId': 'OG004'}, {'value': '45', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '7.04', 'spread': '9.32', 'groupId': 'OG000'}, {'value': '4.89', 'spread': '10.57', 'groupId': 'OG001'}, {'value': '6.92', 'spread': '12.06', 'groupId': 'OG002'}, {'value': '4.29', 'spread': '10.51', 'groupId': 'OG003'}, {'value': '6.50', 'spread': '10.79', 'groupId': 'OG004'}, {'value': '5.76', 'spread': '10.22', 'groupId': 'OG005'}, {'value': '5.11', 'spread': '10.10', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 84', 'description': 'The 36-Item Short Form Health Survey (SF-36v2) is a questionnaire used to assess functional health and well-being and consists of eight domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health.\n\nThe SF-36v2 is summarized into Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. The PCS and MCS scores range from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.', 'unitOfMeasure': 'Number on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis. Number of participants for whom data were collected is indicated for each time point.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '111', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG003', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG004', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG005', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG006', 'title': 'Cohort 2: GDC-0853 Placebo', 'description': 'Participants of Cohort 2 received placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'categories': [{'measurements': [{'value': '9.00', 'spread': '10.57', 'groupId': 'OG000'}, {'value': '8.21', 'spread': '10.22', 'groupId': 'OG001'}, {'value': '8.95', 'spread': '10.04', 'groupId': 'OG002'}, {'value': '7.08', 'spread': '10.88', 'groupId': 'OG003'}, {'value': '9.59', 'spread': '9.02', 'groupId': 'OG004'}, {'value': '8.85', 'spread': '9.57', 'groupId': 'OG005'}, {'value': '5.71', 'spread': '9.24', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 84', 'description': "The FACIT-Fatigue Scale consists of 13 items designed to measure the degree of fatigue experienced by the patient in the previous 7 days. For each question, there are five possible responses: 0 (not at all), 1 (a little bit), 2 (somewhat), 3 (quite a bit), 4 (very much).\n\nA total fatigue score is calculated by summing all items, and possible total scores range from 0 (maximum fatigue) to 52 (no fatigue). A positive change from baseline indicates an improvement in the patient's fatigue (less fatigue).", 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis. Number of participants for whom data were collected is indicated for each time point.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Tender/Painful Joint Count (68 Joint Count)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '111', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG003', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG004', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG005', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG006', 'title': 'Cohort 2: GDC-0853 Placebo', 'description': 'Participants of Cohort 2 received placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'title': 'Week 1 Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}, {'value': '107', 'groupId': 'OG001'}, {'value': '108', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '107', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-2.79', 'spread': '7.25', 'groupId': 'OG000'}, {'value': '-4.12', 'spread': '8.14', 'groupId': 'OG001'}, {'value': '-3.33', 'spread': '9.27', 'groupId': 'OG002'}, {'value': '-3.81', 'spread': '10.85', 'groupId': 'OG003'}, {'value': '-5.58', 'spread': '9.41', 'groupId': 'OG004'}, {'value': '-6.57', 'spread': '8.66', 'groupId': 'OG005'}, {'value': '-3.06', 'spread': '11.01', 'groupId': 'OG006'}]}]}, {'title': 'Week 2 Day 19', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '108', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '109', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-4.33', 'spread': '12.31', 'groupId': 'OG000'}, {'value': '-6.36', 'spread': '10.88', 'groupId': 'OG001'}, {'value': '-5.91', 'spread': '9.38', 'groupId': 'OG002'}, {'value': '-5.78', 'spread': '11.50', 'groupId': 'OG003'}, {'value': '-8.62', 'spread': '10.46', 'groupId': 'OG004'}, {'value': '-6.08', 'spread': '8.53', 'groupId': 'OG005'}, {'value': '-3.92', 'spread': '10.77', 'groupId': 'OG006'}]}]}, {'title': 'Week 4 Day 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '108', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '109', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-6.00', 'spread': '8.89', 'groupId': 'OG000'}, {'value': '-7.90', 'spread': '11.28', 'groupId': 'OG001'}, {'value': '-6.84', 'spread': '9.53', 'groupId': 'OG002'}, {'value': '-7.55', 'spread': '12.97', 'groupId': 'OG003'}, {'value': '-11.61', 'spread': '11.43', 'groupId': 'OG004'}, {'value': '-7.79', 'spread': '7.93', 'groupId': 'OG005'}, {'value': '-4.40', 'spread': '12.37', 'groupId': 'OG006'}]}]}, {'title': 'Week 8 Day 56', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '109', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-9.72', 'spread': '8.20', 'groupId': 'OG000'}, {'value': '-11.57', 'spread': '12.18', 'groupId': 'OG001'}, {'value': '-9.75', 'spread': '10.93', 'groupId': 'OG002'}, {'value': '-10.75', 'spread': '14.37', 'groupId': 'OG003'}, {'value': '-14.12', 'spread': '11.33', 'groupId': 'OG004'}, {'value': '-11.65', 'spread': '10.34', 'groupId': 'OG005'}, {'value': '-4.60', 'spread': '12.41', 'groupId': 'OG006'}]}]}, {'title': 'Week 12 Day 84', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '109', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-10.33', 'spread': '9.40', 'groupId': 'OG000'}, {'value': '-12.72', 'spread': '12.05', 'groupId': 'OG001'}, {'value': '-11.49', 'spread': '11.15', 'groupId': 'OG002'}, {'value': '-10.55', 'spread': '14.37', 'groupId': 'OG003'}, {'value': '-15.49', 'spread': '12.31', 'groupId': 'OG004'}, {'value': '-13.73', 'spread': '12.81', 'groupId': 'OG005'}, {'value': '-7.14', 'spread': '13.32', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': 'Tender Joint Count: a total of 68 joints will be assessed for tenderness. Each joint is assessed for the presence/absence of tenderness. 68 joints are assessed for tenderness and joints are classified as tender/not tender giving a total possible tender joint count score of 0 to 68. A negative change from Baseline indicated improvement.', 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis. Number of participants for whom data were collected is indicated for each time point.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Swollen Joint Count (66 Joint Count)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '111', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG003', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG004', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG005', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG006', 'title': 'Cohort 2: GDC-0853 Placebo', 'description': 'Participants of Cohort 2 received placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'title': 'Week 1 Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}, {'value': '107', 'groupId': 'OG001'}, {'value': '108', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '107', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-1.84', 'spread': '5.19', 'groupId': 'OG000'}, {'value': '-2.89', 'spread': '5.01', 'groupId': 'OG001'}, {'value': '-3.45', 'spread': '6.02', 'groupId': 'OG002'}, {'value': '-3.35', 'spread': '9.38', 'groupId': 'OG003'}, {'value': '-3.94', 'spread': '5.33', 'groupId': 'OG004'}, {'value': '-3.45', 'spread': '4.90', 'groupId': 'OG005'}, {'value': '-1.49', 'spread': '4.49', 'groupId': 'OG006'}]}]}, {'title': 'Week 2 Day 14', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '108', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '109', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-3.95', 'spread': '6.44', 'groupId': 'OG000'}, {'value': '-4.78', 'spread': '5.99', 'groupId': 'OG001'}, {'value': '-5.06', 'spread': '5.14', 'groupId': 'OG002'}, {'value': '-4.23', 'spread': '9.88', 'groupId': 'OG003'}, {'value': '-6.26', 'spread': '5.98', 'groupId': 'OG004'}, {'value': '-3.29', 'spread': '5.69', 'groupId': 'OG005'}, {'value': '-2.96', 'spread': '6.27', 'groupId': 'OG006'}]}]}, {'title': 'Week 4 Day 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '108', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '109', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-4.38', 'spread': '4.55', 'groupId': 'OG000'}, {'value': '-6.33', 'spread': '7.98', 'groupId': 'OG001'}, {'value': '-5.95', 'spread': '6.09', 'groupId': 'OG002'}, {'value': '-5.47', 'spread': '9.26', 'groupId': 'OG003'}, {'value': '-8.50', 'spread': '6.39', 'groupId': 'OG004'}, {'value': '-4.21', 'spread': '6.39', 'groupId': 'OG005'}, {'value': '-3.46', 'spread': '5.62', 'groupId': 'OG006'}]}]}, {'title': 'Week 8 Day 56', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '109', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-6.54', 'spread': '5.78', 'groupId': 'OG000'}, {'value': '-8.06', 'spread': '8.13', 'groupId': 'OG001'}, {'value': '-7.72', 'spread': '7.44', 'groupId': 'OG002'}, {'value': '-7.41', 'spread': '10.82', 'groupId': 'OG003'}, {'value': '-9.60', 'spread': '6.94', 'groupId': 'OG004'}, {'value': '-6.81', 'spread': '6.16', 'groupId': 'OG005'}, {'value': '-3.02', 'spread': '7.76', 'groupId': 'OG006'}]}]}, {'title': 'Week 12 Day 84', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '109', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-7.36', 'spread': '5.88', 'groupId': 'OG000'}, {'value': '-8.89', 'spread': '8.23', 'groupId': 'OG001'}, {'value': '-8.48', 'spread': '7.01', 'groupId': 'OG002'}, {'value': '-8.26', 'spread': '11.48', 'groupId': 'OG003'}, {'value': '-9.94', 'spread': '6.91', 'groupId': 'OG004'}, {'value': '-7.65', 'spread': '6.75', 'groupId': 'OG005'}, {'value': '-4.86', 'spread': '5.84', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': 'Swollen Joint Count: a total of 66 joints will be assessed for swelling. Each joint is assessed for the presence/absence of swelling. 66 joints were assessed for swelling and joints are classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66. A negative change from Baseline indicated improvement.', 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis. Number of participants for whom data were collected is indicated for each time point.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Patient Assessment Score of Arthritis Pain', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '111', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG003', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG004', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG005', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG006', 'title': 'Cohort 2: GDC-0853 Placebo', 'description': 'Participants of Cohort 2 received placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'title': 'Week 1 Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}, {'value': '104', 'groupId': 'OG001'}, {'value': '102', 'groupId': 'OG002'}, {'value': '104', 'groupId': 'OG003'}, {'value': '104', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '45', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-9.00', 'spread': '18.66', 'groupId': 'OG000'}, {'value': '-9.20', 'spread': '20.56', 'groupId': 'OG001'}, {'value': '-11.18', 'spread': '21.64', 'groupId': 'OG002'}, {'value': '-4.12', 'spread': '22.43', 'groupId': 'OG003'}, {'value': '-15.75', 'spread': '18.71', 'groupId': 'OG004'}, {'value': '-11.94', 'spread': '21.25', 'groupId': 'OG005'}, {'value': '-2.76', 'spread': '18.24', 'groupId': 'OG006'}]}]}, {'title': 'Week 2 Day 14', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}, {'value': '104', 'groupId': 'OG001'}, {'value': '106', 'groupId': 'OG002'}, {'value': '105', 'groupId': 'OG003'}, {'value': '107', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '46', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-6.08', 'spread': '21.64', 'groupId': 'OG000'}, {'value': '-12.16', 'spread': '20.09', 'groupId': 'OG001'}, {'value': '-17.08', 'spread': '23.46', 'groupId': 'OG002'}, {'value': '-8.22', 'spread': '25.72', 'groupId': 'OG003'}, {'value': '-18.13', 'spread': '17.71', 'groupId': 'OG004'}, {'value': '-15.08', 'spread': '21.87', 'groupId': 'OG005'}, {'value': '-4.72', 'spread': '17.64', 'groupId': 'OG006'}]}]}, {'title': 'Week 4 Day 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '37', 'groupId': 'OG000'}, {'value': '102', 'groupId': 'OG001'}, {'value': '104', 'groupId': 'OG002'}, {'value': '103', 'groupId': 'OG003'}, {'value': '107', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '48', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-13.41', 'spread': '16.79', 'groupId': 'OG000'}, {'value': '-15.75', 'spread': '21.97', 'groupId': 'OG001'}, {'value': '-18.63', 'spread': '24.87', 'groupId': 'OG002'}, {'value': '-10.08', 'spread': '27.16', 'groupId': 'OG003'}, {'value': '-20.21', 'spread': '21.97', 'groupId': 'OG004'}, {'value': '-16.64', 'spread': '27.86', 'groupId': 'OG005'}, {'value': '-7.54', 'spread': '23.80', 'groupId': 'OG006'}]}]}, {'title': 'Week 8 Day 56', 'denoms': [{'units': 'Participants', 'counts': [{'value': '37', 'groupId': 'OG000'}, {'value': '100', 'groupId': 'OG001'}, {'value': '100', 'groupId': 'OG002'}, {'value': '99', 'groupId': 'OG003'}, {'value': '105', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '45', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-18.38', 'spread': '19.35', 'groupId': 'OG000'}, {'value': '-23.21', 'spread': '22.10', 'groupId': 'OG001'}, {'value': '-25.95', 'spread': '27.50', 'groupId': 'OG002'}, {'value': '-16.37', 'spread': '27.65', 'groupId': 'OG003'}, {'value': '-24.70', 'spread': '22.23', 'groupId': 'OG004'}, {'value': '-21.21', 'spread': '27.13', 'groupId': 'OG005'}, {'value': '-7.13', 'spread': '25.73', 'groupId': 'OG006'}]}]}, {'title': 'Week 12 Day 84', 'denoms': [{'units': 'Participants', 'counts': [{'value': '36', 'groupId': 'OG000'}, {'value': '95', 'groupId': 'OG001'}, {'value': '95', 'groupId': 'OG002'}, {'value': '99', 'groupId': 'OG003'}, {'value': '105', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '44', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-23.14', 'spread': '21.14', 'groupId': 'OG000'}, {'value': '-26.48', 'spread': '23.30', 'groupId': 'OG001'}, {'value': '-30.63', 'spread': '28.49', 'groupId': 'OG002'}, {'value': '-17.88', 'spread': '29.42', 'groupId': 'OG003'}, {'value': '-26.30', 'spread': '23.87', 'groupId': 'OG004'}, {'value': '-26.49', 'spread': '27.65', 'groupId': 'OG005'}, {'value': '-13.98', 'spread': '25.32', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': "Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain", 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis. Number of participants for whom data were collected is indicated for each time point.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Patient Global Assessment Score of Arthritis Pain', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '111', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG003', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG004', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG005', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG006', 'title': 'Cohort 2: GDC-0853 Placebo', 'description': 'Participants of Cohort 2 received placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'title': 'Week 1 Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '103', 'groupId': 'OG002'}, {'value': '104', 'groupId': 'OG003'}, {'value': '104', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '45', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-9.00', 'spread': '15.88', 'groupId': 'OG000'}, {'value': '-10.30', 'spread': '20.82', 'groupId': 'OG001'}, {'value': '-11.82', 'spread': '22.52', 'groupId': 'OG002'}, {'value': '-3.07', 'spread': '20.83', 'groupId': 'OG003'}, {'value': '-18.33', 'spread': '20.81', 'groupId': 'OG004'}, {'value': '-13.15', 'spread': '22.17', 'groupId': 'OG005'}, {'value': '-4.96', 'spread': '19.18', 'groupId': 'OG006'}]}]}, {'title': 'Week 2 Day 14', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}, {'value': '103', 'groupId': 'OG001'}, {'value': '106', 'groupId': 'OG002'}, {'value': '105', 'groupId': 'OG003'}, {'value': '107', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-5.50', 'spread': '20.98', 'groupId': 'OG000'}, {'value': '-13.70', 'spread': '19.63', 'groupId': 'OG001'}, {'value': '-14.84', 'spread': '24.08', 'groupId': 'OG002'}, {'value': '-5.39', 'spread': '26.13', 'groupId': 'OG003'}, {'value': '-18.94', 'spread': '22.33', 'groupId': 'OG004'}, {'value': '-15.46', 'spread': '21.67', 'groupId': 'OG005'}, {'value': '-8.64', 'spread': '19.43', 'groupId': 'OG006'}]}]}, {'title': 'Week 4 Day 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '37', 'groupId': 'OG000'}, {'value': '103', 'groupId': 'OG001'}, {'value': '104', 'groupId': 'OG002'}, {'value': '102', 'groupId': 'OG003'}, {'value': '106', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '48', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-12.11', 'spread': '16.68', 'groupId': 'OG000'}, {'value': '16.10', 'spread': '23.48', 'groupId': 'OG001'}, {'value': '-17.75', 'spread': '22.73', 'groupId': 'OG002'}, {'value': '-6.36', 'spread': '25.99', 'groupId': 'OG003'}, {'value': '-21.78', 'spread': '25.53', 'groupId': 'OG004'}, {'value': '-18.26', 'spread': '27.53', 'groupId': 'OG005'}, {'value': '-10.96', 'spread': '21.54', 'groupId': 'OG006'}]}]}, {'title': 'Week 8 Day 56', 'denoms': [{'units': 'Participants', 'counts': [{'value': '37', 'groupId': 'OG000'}, {'value': '100', 'groupId': 'OG001'}, {'value': '100', 'groupId': 'OG002'}, {'value': '99', 'groupId': 'OG003'}, {'value': '105', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '45', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-19.19', 'spread': '16.88', 'groupId': 'OG000'}, {'value': '-24.06', 'spread': '24.99', 'groupId': 'OG001'}, {'value': '-22.59', 'spread': '26.81', 'groupId': 'OG002'}, {'value': '-14.19', 'spread': '29.80', 'groupId': 'OG003'}, {'value': '-26.77', 'spread': '25.69', 'groupId': 'OG004'}, {'value': '-21.17', 'spread': '25.98', 'groupId': 'OG005'}, {'value': '-11.82', 'spread': '21.66', 'groupId': 'OG006'}]}]}, {'title': 'Week 12 Day 84', 'denoms': [{'units': 'Participants', 'counts': [{'value': '36', 'groupId': 'OG000'}, {'value': '95', 'groupId': 'OG001'}, {'value': '95', 'groupId': 'OG002'}, {'value': '99', 'groupId': 'OG003'}, {'value': '106', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '44', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-23.33', 'spread': '22.03', 'groupId': 'OG000'}, {'value': '-26.67', 'spread': '26.89', 'groupId': 'OG001'}, {'value': '-27.33', 'spread': '27.33', 'groupId': 'OG002'}, {'value': '-16.87', 'spread': '28.68', 'groupId': 'OG003'}, {'value': '-26.24', 'spread': '27.02', 'groupId': 'OG004'}, {'value': '-25.55', 'spread': '27.52', 'groupId': 'OG005'}, {'value': '-13.80', 'spread': '22.17', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': "Participant-assessed arthritis pain was scored on a 100-mm VAS, where the distance from 0 mm represented the participant's self evaluation of arthritis pain (0 mm=none; 100 mm=very severe). Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest, where negative change indicated a decrease in participant-assessed arthritis pain.", 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis. Number of participants for whom data were collected is indicated for each time point.'}, {'type': 'SECONDARY', 'title': "Change From Baseline in Physician's Global Assessment Score of Arthritis", 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '111', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG003', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG004', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG005', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG006', 'title': 'Cohort 2: GDC-0853 Placebo', 'description': 'Participants of Cohort 2 received placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'title': 'Week 1 Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}, {'value': '107', 'groupId': 'OG001'}, {'value': '108', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '107', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-7.89', 'spread': '13.16', 'groupId': 'OG000'}, {'value': '-10.68', 'spread': '15.41', 'groupId': 'OG001'}, {'value': '-12.82', 'spread': '17.03', 'groupId': 'OG002'}, {'value': '-5.85', 'spread': '15.44', 'groupId': 'OG003'}, {'value': '-14.23', 'spread': '16.13', 'groupId': 'OG004'}, {'value': '-9.57', 'spread': '17.10', 'groupId': 'OG005'}, {'value': '-7.66', 'spread': '18.33', 'groupId': 'OG006'}]}]}, {'title': 'Week 2 Day 14', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '106', 'groupId': 'OG001'}, {'value': '109', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '109', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '48', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-11.10', 'spread': '15.65', 'groupId': 'OG000'}, {'value': '-15.86', 'spread': '16.77', 'groupId': 'OG001'}, {'value': '-18.30', 'spread': '19.04', 'groupId': 'OG002'}, {'value': '-9.01', 'spread': '18.07', 'groupId': 'OG003'}, {'value': '-21.33', 'spread': '19.61', 'groupId': 'OG004'}, {'value': '-14.23', 'spread': '18.50', 'groupId': 'OG005'}, {'value': '-9.85', 'spread': '17.55', 'groupId': 'OG006'}]}]}, {'title': 'Week 4 Day 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}, {'value': '104', 'groupId': 'OG001'}, {'value': '106', 'groupId': 'OG002'}, {'value': '108', 'groupId': 'OG003'}, {'value': '108', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '48', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-16.89', 'spread': '19.06', 'groupId': 'OG000'}, {'value': '-22.02', 'spread': '18.61', 'groupId': 'OG001'}, {'value': '-20.92', 'spread': '17.71', 'groupId': 'OG002'}, {'value': '-14.01', 'spread': '21.03', 'groupId': 'OG003'}, {'value': '-28.81', 'spread': '19.34', 'groupId': 'OG004'}, {'value': '-17.70', 'spread': '20.49', 'groupId': 'OG005'}, {'value': '-12.73', 'spread': '20.42', 'groupId': 'OG006'}]}]}, {'title': 'Week 8 Day 56', 'denoms': [{'units': 'Participants', 'counts': [{'value': '37', 'groupId': 'OG000'}, {'value': '101', 'groupId': 'OG001'}, {'value': '103', 'groupId': 'OG002'}, {'value': '102', 'groupId': 'OG003'}, {'value': '108', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '44', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-24.59', 'spread': '15.06', 'groupId': 'OG000'}, {'value': '-28.52', 'spread': '21.11', 'groupId': 'OG001'}, {'value': '-29.67', 'spread': '20.01', 'groupId': 'OG002'}, {'value': '-20.87', 'spread': '23.85', 'groupId': 'OG003'}, {'value': '-36.16', 'spread': '21.82', 'groupId': 'OG004'}, {'value': '-22.40', 'spread': '20.43', 'groupId': 'OG005'}, {'value': '-9.91', 'spread': '19.67', 'groupId': 'OG006'}]}]}, {'title': 'Week 12 Day 84', 'denoms': [{'units': 'Participants', 'counts': [{'value': '37', 'groupId': 'OG000'}, {'value': '98', 'groupId': 'OG001'}, {'value': '96', 'groupId': 'OG002'}, {'value': '102', 'groupId': 'OG003'}, {'value': '107', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '45', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-26.81', 'spread': '16.20', 'groupId': 'OG000'}, {'value': '-32.43', 'spread': '19.24', 'groupId': 'OG001'}, {'value': '-34.48', 'spread': '19.49', 'groupId': 'OG002'}, {'value': '-23.19', 'spread': '23.39', 'groupId': 'OG003'}, {'value': '-37.18', 'spread': '21.02', 'groupId': 'OG004'}, {'value': '-30.82', 'spread': '21.95', 'groupId': 'OG005'}, {'value': '-18.44', 'spread': '21.86', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': "Physician's assessment of participant's disease activity was scored on a 100-mm VAS, where the distance from 0 mm represented the physician's assessment of the participant's disease activity (0 mm=very good; 100 mm=very poor). Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest, where negative change from baseline indicated an improvement in physician-assessed disease activity.", 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis. Number of participants for whom data were collected is indicated for each time point.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in C-Reactive Protein (CRP) Levels', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '111', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG003', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG004', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG005', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG006', 'title': 'Cohort 2: GDC-0853 Placebo', 'description': 'Participants of Cohort 2 received placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'title': 'Week 1 Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '37', 'groupId': 'OG000'}, {'value': '106', 'groupId': 'OG001'}, {'value': '107', 'groupId': 'OG002'}, {'value': '109', 'groupId': 'OG003'}, {'value': '107', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '46', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.14', 'spread': '2.09', 'groupId': 'OG000'}, {'value': '0.30', 'spread': '2.58', 'groupId': 'OG001'}, {'value': '0.22', 'spread': '2.49', 'groupId': 'OG002'}, {'value': '0.01', 'spread': '1.29', 'groupId': 'OG003'}, {'value': '-1.21', 'spread': '2.37', 'groupId': 'OG004'}, {'value': '-0.12', 'spread': '2.60', 'groupId': 'OG005'}, {'value': '-0.10', 'spread': '1.76', 'groupId': 'OG006'}]}]}, {'title': 'Week 2 Day 14', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}, {'value': '106', 'groupId': 'OG001'}, {'value': '108', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '109', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.27', 'spread': '1.78', 'groupId': 'OG000'}, {'value': '-0.10', 'spread': '1.92', 'groupId': 'OG001'}, {'value': '-0.21', 'spread': '2.29', 'groupId': 'OG002'}, {'value': '-0.12', 'spread': '1.53', 'groupId': 'OG003'}, {'value': '-0.93', 'spread': '2.70', 'groupId': 'OG004'}, {'value': '-0.20', 'spread': '2.38', 'groupId': 'OG005'}, {'value': '-0.25', 'spread': '2.60', 'groupId': 'OG006'}]}]}, {'title': 'Week 4 Day 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '37', 'groupId': 'OG000'}, {'value': '103', 'groupId': 'OG001'}, {'value': '105', 'groupId': 'OG002'}, {'value': '105', 'groupId': 'OG003'}, {'value': '109', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '48', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0.15', 'spread': '2.45', 'groupId': 'OG000'}, {'value': '-0.25', 'spread': '2.55', 'groupId': 'OG001'}, {'value': '-0.44', 'spread': '2.30', 'groupId': 'OG002'}, {'value': '0.14', 'spread': '2.00', 'groupId': 'OG003'}, {'value': '-1.11', 'spread': '2.17', 'groupId': 'OG004'}, {'value': '-0.30', 'spread': '2.58', 'groupId': 'OG005'}, {'value': '-0.24', 'spread': '2.80', 'groupId': 'OG006'}]}]}, {'title': 'Week 8 Day 56', 'denoms': [{'units': 'Participants', 'counts': [{'value': '36', 'groupId': 'OG000'}, {'value': '100', 'groupId': 'OG001'}, {'value': '103', 'groupId': 'OG002'}, {'value': '100', 'groupId': 'OG003'}, {'value': '106', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '45', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-0.49', 'spread': '1.66', 'groupId': 'OG000'}, {'value': '-0.52', 'spread': '1.83', 'groupId': 'OG001'}, {'value': '-0.89', 'spread': '3.16', 'groupId': 'OG002'}, {'value': '-0.39', 'spread': '1.64', 'groupId': 'OG003'}, {'value': '-1.14', 'spread': '2.39', 'groupId': 'OG004'}, {'value': '-1.19', 'spread': '2.18', 'groupId': 'OG005'}, {'value': '-0.26', 'spread': '2.55', 'groupId': 'OG006'}]}]}, {'title': 'Week 12 Day 84', 'denoms': [{'units': 'Participants', 'counts': [{'value': '37', 'groupId': 'OG000'}, {'value': '97', 'groupId': 'OG001'}, {'value': '97', 'groupId': 'OG002'}, {'value': '102', 'groupId': 'OG003'}, {'value': '106', 'groupId': 'OG004'}, {'value': '47', 'groupId': 'OG005'}, {'value': '44', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-0.59', 'spread': '1.43', 'groupId': 'OG000'}, {'value': '-0.77', 'spread': '1.89', 'groupId': 'OG001'}, {'value': '-1.30', 'spread': '2.88', 'groupId': 'OG002'}, {'value': '-0.45', 'spread': '1.71', 'groupId': 'OG003'}, {'value': '-1.03', 'spread': '2.01', 'groupId': 'OG004'}, {'value': '-1.55', 'spread': '2.35', 'groupId': 'OG005'}, {'value': '-0.56', 'spread': '2.75', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': 'C-reactive protein is a biological marker of inflammation and is measured in nanograms per milliliter (ng/mL)', 'unitOfMeasure': '(ng/mL) nanograms per milliliter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis. Number of participants for whom data were collected is indicated for each time point.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}, {'value': '110', 'groupId': 'OG003'}, {'value': '111', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}, {'value': '50', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG003', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG004', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG005', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG006', 'title': 'Cohort 2: GDC-0853 Placebo', 'description': 'Participants of Cohort 2 received placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'title': 'Week 1 Day 7', 'denoms': [{'units': 'Participants', 'counts': [{'value': '37', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '100', 'groupId': 'OG002'}, {'value': '99', 'groupId': 'OG003'}, {'value': '104', 'groupId': 'OG004'}, {'value': '44', 'groupId': 'OG005'}, {'value': '45', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-0.20', 'spread': '0.37', 'groupId': 'OG000'}, {'value': '-0.15', 'spread': '0.35', 'groupId': 'OG001'}, {'value': '-0.22', 'spread': '0.48', 'groupId': 'OG002'}, {'value': '-0.10', 'spread': '0.38', 'groupId': 'OG003'}, {'value': '-0.26', 'spread': '0.42', 'groupId': 'OG004'}, {'value': '-0.19', 'spread': '0.36', 'groupId': 'OG005'}, {'value': '-0.14', 'spread': '0.46', 'groupId': 'OG006'}]}]}, {'title': 'Week 2 Day 14', 'denoms': [{'units': 'Participants', 'counts': [{'value': '37', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '105', 'groupId': 'OG002'}, {'value': '102', 'groupId': 'OG003'}, {'value': '108', 'groupId': 'OG004'}, {'value': '45', 'groupId': 'OG005'}, {'value': '47', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-0.24', 'spread': '0.39', 'groupId': 'OG000'}, {'value': '-0.23', 'spread': '0.46', 'groupId': 'OG001'}, {'value': '-0.28', 'spread': '0.50', 'groupId': 'OG002'}, {'value': '-0.17', 'spread': '0.45', 'groupId': 'OG003'}, {'value': '-0.35', 'spread': '0.47', 'groupId': 'OG004'}, {'value': '-0.23', 'spread': '0.45', 'groupId': 'OG005'}, {'value': '-0.13', 'spread': '0.49', 'groupId': 'OG006'}]}]}, {'title': 'Week 4 Day 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '36', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '103', 'groupId': 'OG002'}, {'value': '100', 'groupId': 'OG003'}, {'value': '106', 'groupId': 'OG004'}, {'value': '44', 'groupId': 'OG005'}, {'value': '46', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-0.34', 'spread': '0.47', 'groupId': 'OG000'}, {'value': '-0.32', 'spread': '0.48', 'groupId': 'OG001'}, {'value': '-0.40', 'spread': '0.50', 'groupId': 'OG002'}, {'value': '-0.19', 'spread': '0.56', 'groupId': 'OG003'}, {'value': '-0.50', 'spread': '0.50', 'groupId': 'OG004'}, {'value': '-0.23', 'spread': '0.42', 'groupId': 'OG005'}, {'value': '-0.17', 'spread': '0.44', 'groupId': 'OG006'}]}]}, {'title': 'Week 8 Day 56', 'denoms': [{'units': 'Participants', 'counts': [{'value': '36', 'groupId': 'OG000'}, {'value': '98', 'groupId': 'OG001'}, {'value': '101', 'groupId': 'OG002'}, {'value': '96', 'groupId': 'OG003'}, {'value': '106', 'groupId': 'OG004'}, {'value': '44', 'groupId': 'OG005'}, {'value': '44', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-0.49', 'spread': '0.47', 'groupId': 'OG000'}, {'value': '-0.44', 'spread': '0.56', 'groupId': 'OG001'}, {'value': '-0.56', 'spread': '0.55', 'groupId': 'OG002'}, {'value': '-0.40', 'spread': '0.64', 'groupId': 'OG003'}, {'value': '-0.60', 'spread': '0.55', 'groupId': 'OG004'}, {'value': '-0.45', 'spread': '0.50', 'groupId': 'OG005'}, {'value': '-0.23', 'spread': '0.55', 'groupId': 'OG006'}]}]}, {'title': 'Week 12 Day 84', 'denoms': [{'units': 'Participants', 'counts': [{'value': '35', 'groupId': 'OG000'}, {'value': '97', 'groupId': 'OG001'}, {'value': '100', 'groupId': 'OG002'}, {'value': '95', 'groupId': 'OG003'}, {'value': '107', 'groupId': 'OG004'}, {'value': '44', 'groupId': 'OG005'}, {'value': '43', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '-0.51', 'spread': '0.57', 'groupId': 'OG000'}, {'value': '-0.57', 'spread': '0.57', 'groupId': 'OG001'}, {'value': '-0.65', 'spread': '0.60', 'groupId': 'OG002'}, {'value': '-0.35', 'spread': '0.68', 'groupId': 'OG003'}, {'value': '-0.65', 'spread': '0.61', 'groupId': 'OG004'}, {'value': '-0.53', 'spread': '0.61', 'groupId': 'OG005'}, {'value': '-0.30', 'spread': '0.62', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': "The Stanford Health Assessment Questionnaire disability index is a patient-reported outcome used to assess difficulty in performing activities of daily living. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities.\n\nTo respond to each question, a four-level response with higher scores showing larger functional limitations, was chosen. Scoring is as follows with respect to performance of participant's everyday activities: 0 (equals)=without difficulties; 1= with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. The composite HAQ-DI score is the mean of the eight domain scores and the score ranges from 0 (no functional impairment) to 3 (maximum functional impairment). A negative change from baseline indicates improvement.", 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis. Number of participants for whom data were collected is indicated for each time point.'}, {'type': 'SECONDARY', 'title': 'Area Under the Concentration Time Curve From Time 0 to Time 24 of GDC-0853 at Steady State (AUC0-24,ss)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '106', 'groupId': 'OG001'}, {'value': '108', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG003', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'categories': [{'measurements': [{'value': '1170', 'spread': '1600', 'groupId': 'OG000'}, {'value': '2910', 'spread': '3180', 'groupId': 'OG001'}, {'value': '9380', 'spread': '4860', 'groupId': 'OG002'}, {'value': '9890', 'spread': '5480', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose (0 hours) up to 10 hours post-dose on Day 28', 'description': 'The Pharmacokinetics (PK) evaluation may include, but will not be limited to, plasma GDC-0853 concentrations and population PK model estimated PK exposures (area under the plasma concentration-time curve \\[AUC\\]. AUC was measured in Nanograms(ng) per millilitre(mL)\\*hour (hr)', 'unitOfMeasure': 'Ng/mL*(hr)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis. Number of participants for whom data were collected is indicated for each time point. Data were presented only for arms in which GDC-0853 was administered.'}, {'type': 'SECONDARY', 'title': 'Maximum Observed Plasma Concentration of GDC-0853 at Steady State (Cmax,ss)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '106', 'groupId': 'OG001'}, {'value': '108', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG003', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'categories': [{'measurements': [{'value': '110', 'spread': '116', 'groupId': 'OG000'}, {'value': '280', 'spread': '223', 'groupId': 'OG001'}, {'value': '591', 'spread': '282', 'groupId': 'OG002'}, {'value': '621', 'spread': '302', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose (0 hours) up to 10 hours post-dose on Day 28', 'description': 'Cmax is the maximum (peak) plasma concentration over the dosing interval at steady state (ss)', 'unitOfMeasure': 'Nanogram per Milliliter (ng/mL)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis. Number of participants for whom data were collected is indicated for each time point. Data were presented only for arms in which GDC-0853 was administered.'}, {'type': 'SECONDARY', 'title': 'Minimum Observed Plasma Concentration of GDC-0853 at Steady State (Cmin,ss)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '106', 'groupId': 'OG001'}, {'value': '108', 'groupId': 'OG002'}, {'value': '48', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'OG003', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'classes': [{'categories': [{'measurements': [{'value': '22.4', 'spread': '41.0', 'groupId': 'OG000'}, {'value': '54.7', 'spread': '83.4', 'groupId': 'OG001'}, {'value': '250', 'spread': '146', 'groupId': 'OG002'}, {'value': '263', 'spread': '170', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose (0 hours) up to 10 hours post-dose on Day 28', 'description': 'Cmin is the minimum concentration over the dosing interval at steady state (ss)', 'unitOfMeasure': 'Nanogram per Milliliter (ng/mL)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis. Number of participants for whom data were collected is indicated for each time point. Data were presented only for arms in which GDC-0853 was administered.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'FG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'FG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'FG003', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'FG004', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'FG005', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'FG006', 'title': 'Cohort 2: GDC-0853 Placebo', 'description': 'Participants of Cohort 2 received placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'comment': 'SAF population', 'achievements': [{'groupId': 'FG000', 'numSubjects': '40'}, {'groupId': 'FG001', 'numSubjects': '109'}, {'groupId': 'FG002', 'numSubjects': '110'}, {'groupId': 'FG003', 'numSubjects': '110'}, {'groupId': 'FG004', 'numSubjects': '111'}, {'groupId': 'FG005', 'numSubjects': '49'}, {'groupId': 'FG006', 'numSubjects': '49'}]}, {'type': 'Randomized', 'comment': 'ITT population', 'achievements': [{'groupId': 'FG000', 'numSubjects': '40'}, {'groupId': 'FG001', 'numSubjects': '109'}, {'groupId': 'FG002', 'numSubjects': '110'}, {'groupId': 'FG003', 'numSubjects': '110'}, {'groupId': 'FG004', 'numSubjects': '111'}, {'groupId': 'FG005', 'numSubjects': '48'}, {'groupId': 'FG006', 'numSubjects': '50'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '37'}, {'groupId': 'FG001', 'numSubjects': '100'}, {'groupId': 'FG002', 'numSubjects': '102'}, {'groupId': 'FG003', 'numSubjects': '102'}, {'groupId': 'FG004', 'numSubjects': '108'}, {'groupId': 'FG005', 'numSubjects': '48'}, {'groupId': 'FG006', 'numSubjects': '44'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '9'}, {'groupId': 'FG002', 'numSubjects': '8'}, {'groupId': 'FG003', 'numSubjects': '8'}, {'groupId': 'FG004', 'numSubjects': '3'}, {'groupId': 'FG005', 'numSubjects': '1'}, {'groupId': 'FG006', 'numSubjects': '5'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '3'}, {'groupId': 'FG002', 'numSubjects': '4'}, {'groupId': 'FG003', 'numSubjects': '4'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '1'}]}, {'type': 'Death', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}]}, {'type': 'Lack of Efficacy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '4'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '1'}, {'groupId': 'FG006', 'numSubjects': '1'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '1'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '3'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '2'}]}]}], 'recruitmentDetails': '578 participants were enrolled in the study and 578 were dosed. One (1) subject in Cohort 2 in the Placebo arm was incorrectly dosed with the High Dose. The ITT data set included participants according to their randomization while SAF data set included participants according to the treatment administered.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'BG000'}, {'value': '109', 'groupId': 'BG001'}, {'value': '110', 'groupId': 'BG002'}, {'value': '110', 'groupId': 'BG003'}, {'value': '111', 'groupId': 'BG004'}, {'value': '49', 'groupId': 'BG005'}, {'value': '49', 'groupId': 'BG006'}, {'value': '578', 'groupId': 'BG007'}]}], 'groups': [{'id': 'BG000', 'title': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'BG001', 'title': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'BG002', 'title': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'BG003', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'BG004', 'title': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': 'Participants of Cohort 1 received placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'BG005', 'title': 'Cohort 2: GDC-0853 High Dose', 'description': 'Participants of Cohort 2 received GDC-0853 high dose, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'BG006', 'title': 'Cohort 2: GDC-0853 Placebo', 'description': 'Participants of Cohort 2 received placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants remained on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week were allowed only if there was clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigators discretion.'}, {'id': 'BG007', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '35', 'groupId': 'BG000'}, {'value': '95', 'groupId': 'BG001'}, {'value': '99', 'groupId': 'BG002'}, {'value': '98', 'groupId': 'BG003'}, {'value': '98', 'groupId': 'BG004'}, {'value': '41', 'groupId': 'BG005'}, {'value': '40', 'groupId': 'BG006'}, {'value': '506', 'groupId': 'BG007'}]}, {'title': '>=65 years', 'measurements': [{'value': '5', 'groupId': 'BG000'}, {'value': '14', 'groupId': 'BG001'}, {'value': '11', 'groupId': 'BG002'}, {'value': '12', 'groupId': 'BG003'}, {'value': '13', 'groupId': 'BG004'}, {'value': '8', 'groupId': 'BG005'}, {'value': '9', 'groupId': 'BG006'}, {'value': '72', 'groupId': 'BG007'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '52.3', 'spread': '12.0', 'groupId': 'BG000'}, {'value': '50.4', 'spread': '11.0', 'groupId': 'BG001'}, {'value': '49.9', 'spread': '12.4', 'groupId': 'BG002'}, {'value': '50.2', 'spread': '11.6', 'groupId': 'BG003'}, {'value': '49.9', 'spread': '12.4', 'groupId': 'BG004'}, {'value': '51.3', 'spread': '13.2', 'groupId': 'BG005'}, {'value': '54.6', 'spread': '11.5', 'groupId': 'BG006'}, {'value': '50.7', 'spread': '12.0', 'groupId': 'BG007'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '35', 'groupId': 'BG000'}, {'value': '92', 'groupId': 'BG001'}, {'value': '85', 'groupId': 'BG002'}, {'value': '90', 'groupId': 'BG003'}, {'value': '87', 'groupId': 'BG004'}, {'value': '37', 'groupId': 'BG005'}, {'value': '37', 'groupId': 'BG006'}, {'value': '463', 'groupId': 'BG007'}]}, {'title': 'Male', 'measurements': [{'value': '5', 'groupId': 'BG000'}, {'value': '17', 'groupId': 'BG001'}, {'value': '25', 'groupId': 'BG002'}, {'value': '20', 'groupId': 'BG003'}, {'value': '24', 'groupId': 'BG004'}, {'value': '12', 'groupId': 'BG005'}, {'value': '12', 'groupId': 'BG006'}, {'value': '115', 'groupId': 'BG007'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'title': 'American Indian or Alaska native', 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '8', 'groupId': 'BG001'}, {'value': '12', 'groupId': 'BG002'}, {'value': '11', 'groupId': 'BG003'}, {'value': '9', 'groupId': 'BG004'}, {'value': '6', 'groupId': 'BG005'}, {'value': '5', 'groupId': 'BG006'}, {'value': '51', 'groupId': 'BG007'}]}]}, {'title': 'Asian', 'categories': [{'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '1', 'groupId': 'BG007'}]}]}, {'title': 'Black of African American', 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '3', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}, {'value': '2', 'groupId': 'BG006'}, {'value': '10', 'groupId': 'BG007'}]}]}, {'title': 'White', 'categories': [{'measurements': [{'value': '36', 'groupId': 'BG000'}, {'value': '96', 'groupId': 'BG001'}, {'value': '96', 'groupId': 'BG002'}, {'value': '95', 'groupId': 'BG003'}, {'value': '99', 'groupId': 'BG004'}, {'value': '42', 'groupId': 'BG005'}, {'value': '42', 'groupId': 'BG006'}, {'value': '506', 'groupId': 'BG007'}]}]}, {'title': 'Multiple', 'categories': [{'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '7', 'groupId': 'BG007'}]}]}, {'title': 'Unknown', 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '3', 'groupId': 'BG007'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'description': 'Race', 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'title': 'Hispanic or Latino', 'categories': [{'measurements': [{'value': '8', 'groupId': 'BG000'}, {'value': '38', 'groupId': 'BG001'}, {'value': '40', 'groupId': 'BG002'}, {'value': '38', 'groupId': 'BG003'}, {'value': '39', 'groupId': 'BG004'}, {'value': '17', 'groupId': 'BG005'}, {'value': '15', 'groupId': 'BG006'}, {'value': '195', 'groupId': 'BG007'}]}]}, {'title': 'Not Hispanic or Latino', 'categories': [{'measurements': [{'value': '31', 'groupId': 'BG000'}, {'value': '68', 'groupId': 'BG001'}, {'value': '69', 'groupId': 'BG002'}, {'value': '72', 'groupId': 'BG003'}, {'value': '70', 'groupId': 'BG004'}, {'value': '32', 'groupId': 'BG005'}, {'value': '33', 'groupId': 'BG006'}, {'value': '375', 'groupId': 'BG007'}]}]}, {'title': 'Not Stated', 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '1', 'groupId': 'BG006'}, {'value': '3', 'groupId': 'BG007'}]}]}, {'title': 'Unknown', 'categories': [{'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '2', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '5', 'groupId': 'BG007'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'description': 'Ethnicity', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'Safety population (SAF) included all subjects that received treatment.'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2017-03-10', 'size': 4969336, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_001.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2020-06-01T10:54', 'hasProtocol': True}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 578}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2016-09-09', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2020-06', 'completionDateStruct': {'date': '2018-07-02', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2020-06-01', 'studyFirstSubmitDate': '2016-07-12', 'resultsFirstSubmitDate': '2019-07-02', 'studyFirstSubmitQcDate': '2016-07-12', 'lastUpdatePostDateStruct': {'date': '2020-06-12', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2019-08-20', 'studyFirstPostDateStruct': {'date': '2016-07-14', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2019-09-10', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2018-07-02', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Day 84, Comparison Between GDC-0853 and Placebo (Cohort 1)', 'timeFrame': 'Day 84', 'description': "ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \\[either C-reactive protein or Erythrocyte Sedimentation Rate\\]."}, {'measure': 'Percentage of Participants With Adverse Events', 'timeFrame': 'Day 1 up to 8 weeks after last dose (up to Week 20)', 'description': 'An Adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A SAE was any experience that suggested a significant hazard, contraindication, side effect or precaution that: resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was medically significant.'}], 'secondaryOutcomes': [{'measure': 'Percentage of Participants Achieving ACR50 Response at Day 84, Comparison Between GDC-0853 and Adalimumab (Cohort 1)', 'timeFrame': 'Day 84', 'description': "ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \\[either C-reactive protein or Erythrocyte Sedimentation Rate\\]."}, {'measure': 'Percentage of Participants Achieving ACR50 Response at Day 84, Comparison Between GDC-0853 and Placebo (Cohort 2)', 'timeFrame': 'Day 84', 'description': "ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \\[either C-reactive protein or Erythrocyte Sedimentation Rate\\]."}, {'measure': 'Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': "ACR20 response is defined as a ≥ 20% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \\[either C-reactive protein or Erythrocyte Sedimentation Rate\\]"}, {'measure': 'Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': "ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \\[either C-reactive protein or Erythrocyte Sedimentation Rate\\]."}, {'measure': 'Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': "ACR70 response is defined as a ≥ 70% improvement (reduction) compared with Baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \\[either C-reactive protein or Erythrocyte Sedimentation Rate\\]."}, {'measure': 'Change in Disease Activity Score From Baseline Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': "The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \\[28 joints\\], swollen joint count (SJC) \\[28 joints\\], patient's global assessment of disease activity \\[visual analog scale: 0=no disease activity to 100=maximum disease activity\\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \\< 2.6."}, {'measure': 'Change in Disease Activity Score From Baseline Based on 28-Joints Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP])', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': "The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \\[28 joints\\], swollen joint count (SJC) \\[28 joints\\], patient's global assessment of disease activity \\[visual analog scale: 0=no disease activity to 100=maximum disease activity\\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \\< 2.6."}, {'measure': 'Change in Disease Activity Score From Baseline Based on 28-Joints Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 [ESR])', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': "The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \\[28 joints\\], swollen joint count (SJC) \\[28 joints\\], patient's global assessment of disease activity \\[visual analog scale: 0=no disease activity to 100=maximum disease activity\\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \\< 2.6."}, {'measure': 'Change in Disease Activity Score From Baseline Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': "The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \\[28 joints\\], swollen joint count (SJC) \\[28 joints\\], patient's global assessment of disease activity \\[visual analog scale: 0=no disease activity to 100=maximum disease activity\\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \\< 2.6."}, {'measure': 'Percentage of Participants With DAS Low Disease Activity', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': "The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \\[28 joints\\], swollen joint count (SJC) \\[28 joints\\], patient's global assessment of disease activity \\[visual analog scale: 0=no disease activity to 100=maximum disease activity\\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. LDAS is defined as DAS28 ≤ 3.2"}, {'measure': 'Percentage of Participants With DAS Remission', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': "The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \\[28 joints\\], swollen joint count (SJC) \\[28 joints\\], patient's global assessment of disease activity \\[visual analog scale: 0=no disease activity to 100=maximum disease activity\\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \\< 2.6"}, {'measure': 'Percentage of Participants Meeting the Boolean-based Remission Criteria', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': 'Boolean Remission is defined as Tender joint count less than 1, Swollen joint count less than 1, CRP less than 1 mg/dL, patient global assessment less than 1 (on 0 to 10 VAS scale).'}, {'measure': 'Change From Baseline in Clinical Disease Activity Index (CDAI)', 'timeFrame': 'Baseline, Days 7, 14, 28, 56 and 84', 'description': 'CDAI was derived as the sum of the following: tender joint count (TJC), swollen joint count (SJC), participant global assessment (PGA) of disease activity, and physician assessment of disease activity. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA and physician assessment of disease activity were scored 0-100 millimeters (mm) and rounded to the nearest centimeter (cm) on a visual analog scale (VAS), where higher scores indicate greater perceived disease activity. The total CDAI score range was 0-76, where higher scores indicate increased disease activity. Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest. Negative values indicate improvement/reduction in RA disease activity.'}, {'measure': 'Percentage of Participants Meeting the CDAI-based Remission Criteria', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': "Clinical Disease Activity Index is defined as CDAI= : SJC(28) + TJC(28) + PGA + MDG where TJC and SJC are the tender and swollen joint counts from 28 joints, PGA is the patient's global assessment of disease activity (on a 0-10 scale) and MDG is physician global assessment of disease activity (on a 0-10 scale). The cutoff value for CDAI remission is \\<=2.8."}, {'measure': 'Change From Baseline in Simplified Disease Activity Index (SDAI)', 'timeFrame': 'Baseline, Days 7, 14, 28, 56 and 84', 'description': 'Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\\< 3.3 indicates disease remission, \\> 3.4 to 11 indicates low disease activity, \\> 11 to 26 indicates moderate disease activity, and \\> 26 indicates high disease activity'}, {'measure': 'Percentage of Participants Meeting the SDAI-based Remission Criteria', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': 'The SDAI was the numerical sum of five outcome parameter: SJC and TJC (based on a 28-joint assessment), PGA and MDG (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. The SDAI =\\< 3.3 indicates disease remission'}, {'measure': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Version 2.0 (V2) Scores for Physical and Mental Components', 'timeFrame': 'Day 84', 'description': 'The 36-Item Short Form Health Survey (SF-36v2) is a questionnaire used to assess functional health and well-being and consists of eight domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health.\n\nThe SF-36v2 is summarized into Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. The PCS and MCS scores range from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.'}, {'measure': 'Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score', 'timeFrame': 'Day 84', 'description': "The FACIT-Fatigue Scale consists of 13 items designed to measure the degree of fatigue experienced by the patient in the previous 7 days. For each question, there are five possible responses: 0 (not at all), 1 (a little bit), 2 (somewhat), 3 (quite a bit), 4 (very much).\n\nA total fatigue score is calculated by summing all items, and possible total scores range from 0 (maximum fatigue) to 52 (no fatigue). A positive change from baseline indicates an improvement in the patient's fatigue (less fatigue)."}, {'measure': 'Change From Baseline in Tender/Painful Joint Count (68 Joint Count)', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': 'Tender Joint Count: a total of 68 joints will be assessed for tenderness. Each joint is assessed for the presence/absence of tenderness. 68 joints are assessed for tenderness and joints are classified as tender/not tender giving a total possible tender joint count score of 0 to 68. A negative change from Baseline indicated improvement.'}, {'measure': 'Change From Baseline in Swollen Joint Count (66 Joint Count)', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': 'Swollen Joint Count: a total of 66 joints will be assessed for swelling. Each joint is assessed for the presence/absence of swelling. 66 joints were assessed for swelling and joints are classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66. A negative change from Baseline indicated improvement.'}, {'measure': 'Change From Baseline in Patient Assessment Score of Arthritis Pain', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': "Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain"}, {'measure': 'Change From Baseline in Patient Global Assessment Score of Arthritis Pain', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': "Participant-assessed arthritis pain was scored on a 100-mm VAS, where the distance from 0 mm represented the participant's self evaluation of arthritis pain (0 mm=none; 100 mm=very severe). Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest, where negative change indicated a decrease in participant-assessed arthritis pain."}, {'measure': "Change From Baseline in Physician's Global Assessment Score of Arthritis", 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': "Physician's assessment of participant's disease activity was scored on a 100-mm VAS, where the distance from 0 mm represented the physician's assessment of the participant's disease activity (0 mm=very good; 100 mm=very poor). Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest, where negative change from baseline indicated an improvement in physician-assessed disease activity."}, {'measure': 'Change From Baseline in C-Reactive Protein (CRP) Levels', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': 'C-reactive protein is a biological marker of inflammation and is measured in nanograms per milliliter (ng/mL)'}, {'measure': 'Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score', 'timeFrame': 'Days 7, 14, 28, 56, and 84', 'description': "The Stanford Health Assessment Questionnaire disability index is a patient-reported outcome used to assess difficulty in performing activities of daily living. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities.\n\nTo respond to each question, a four-level response with higher scores showing larger functional limitations, was chosen. Scoring is as follows with respect to performance of participant's everyday activities: 0 (equals)=without difficulties; 1= with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. The composite HAQ-DI score is the mean of the eight domain scores and the score ranges from 0 (no functional impairment) to 3 (maximum functional impairment). A negative change from baseline indicates improvement."}, {'measure': 'Area Under the Concentration Time Curve From Time 0 to Time 24 of GDC-0853 at Steady State (AUC0-24,ss)', 'timeFrame': 'Pre-dose (0 hours) up to 10 hours post-dose on Day 28', 'description': 'The Pharmacokinetics (PK) evaluation may include, but will not be limited to, plasma GDC-0853 concentrations and population PK model estimated PK exposures (area under the plasma concentration-time curve \\[AUC\\]. AUC was measured in Nanograms(ng) per millilitre(mL)\\*hour (hr)'}, {'measure': 'Maximum Observed Plasma Concentration of GDC-0853 at Steady State (Cmax,ss)', 'timeFrame': 'Pre-dose (0 hours) up to 10 hours post-dose on Day 28', 'description': 'Cmax is the maximum (peak) plasma concentration over the dosing interval at steady state (ss)'}, {'measure': 'Minimum Observed Plasma Concentration of GDC-0853 at Steady State (Cmin,ss)', 'timeFrame': 'Pre-dose (0 hours) up to 10 hours post-dose on Day 28', 'description': 'Cmin is the minimum concentration over the dosing interval at steady state (ss)'}]}, 'conditionsModule': {'conditions': ['Rheumatoid Arthritis']}, 'descriptionModule': {'briefSummary': 'This is a multicenter, Phase II, randomized, double-blind, placebo-controlled, active comparator (Cohort 1 only), parallel-group, dose-ranging study to evaluate the efficacy and safety of GDC-0853 in participants with moderate to severe active RA and an inadequate response to previous methotrexate (MTX) therapy (Cohort 1) or MTX and tumor necrosis factor (TNF) therapy who may have also had exposure to no more than one non-TNF inhibitor biologic (Cohort 2).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Have a diagnosis of adult-onset RA as defined by the 2010 American College of Rheumatology/European League Against Rheumatism Classification Criteria for RA\n* RA disease activity by joint counts and laboratory markers of inflammation: greater than or equal to (\\>=) 6 tender/painful joints on motion (68 joint count) and \\>= 6 swollen joints (66 joint count) at both screening and Day 1 (randomization)\n* For MTX-inadequate response (IR) participants: must have had an inadequate response to MTX\n* For TNF-IR participants: must have had an inadequate response or intolerance to previous treatment with at least 1 and no more than 2 biologic TNF-alpha inhibitors and may have also been exposed to no more than one biologic non-TNF-alpha inhibitor\n* High sensitivity C-reactive protein of \\>= 0.400 milligrams per deciliter (mg/dL) for Cohort 1 and \\>= 0.650 mg/dL for Cohort 2 at screening\n\nExclusion Criteria:\n\n* History of or current inflammatory joint disease other than RA or other systemic autoimmune disorder\n* For MTX-IR participants: History of treatment with any TNF inhibitor, including biosimilar equivalents and history of treatment with biologic non-TNF-alpha inhibitor for RA\n* For all participants: Previous treatment with cell-depleting therapy including B cell-depleting therapy (e.g., anti-cluster of differentiation 20-directed therapy such as rituximab), tofacitinib, or other Janus kinase inhibitor(s), or alkylating agents\n* Current treatment with medications that are well known to prolong the QT interval at doses that have a clinically meaningful effect on QT\n* History of non-gallstone-related pancreatitis or chronic pancreatitis\n* Evidence of serious uncontrolled concomitant cardiac, neurologic, pulmonary, renal, hepatic, endocrine, metabolic, or gastrointestinal disease\n* Evidence of chronic and/or active hepatitis B or C\n* Women who are pregnant, nursing (breast feeding), or intending to become pregnant during the study or within 60 days after completion of the study'}, 'identificationModule': {'nctId': 'NCT02833350', 'briefTitle': 'Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)', 'organization': {'class': 'INDUSTRY', 'fullName': 'Genentech, Inc.'}, 'officialTitle': 'A Two-Cohort Randomized Phase II, Double-Blind, Parallel Group Study in Patients With Active Rheumatoid Arthritis Evaluating the Efficacy and Safety of GDC-0853 Compared With Placebo and Adalimumab in Patients With an Inadequate Response to Previous Methotrexate Therapy (Cohort 1) and Compared With Placebo in Patients With an Inadequate Response or Intolerance to Previous TNF Therapy (Cohort 2)', 'orgStudyIdInfo': {'id': 'GA29350'}, 'secondaryIdInfos': [{'id': '2016-000335-40', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'description': "Participants of Cohort 1 will receive GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.", 'interventionNames': ['Drug: GDC-0853', 'Drug: Folic Acid', 'Drug: MTX', 'Drug: Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'description': "Participants of Cohort 1 will receive GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.", 'interventionNames': ['Drug: GDC-0853', 'Drug: Folic Acid', 'Drug: MTX', 'Drug: Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'description': "Participants of Cohort 1 will receive GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.", 'interventionNames': ['Drug: GDC-0853', 'Drug: Folic Acid', 'Drug: MTX', 'Drug: Placebo']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'description': "Participants of Cohort 1 will receive placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.", 'interventionNames': ['Drug: Adalimumab', 'Drug: Folic Acid', 'Drug: MTX', 'Drug: Placebo']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'description': "Participants of Cohort 1 will receive placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.", 'interventionNames': ['Drug: Folic Acid', 'Drug: MTX', 'Drug: Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'Cohort 2: GDC-0853 High Dose', 'description': "Participants of Cohort 2 will receive GDC-0853 high dose, orally twice daily for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.", 'interventionNames': ['Drug: GDC-0853', 'Drug: Folic Acid', 'Drug: MTX']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Cohort 2: GDC-0853 Placebo', 'description': "Participants of Cohort 2 will receive placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.", 'interventionNames': ['Drug: Folic Acid', 'Drug: MTX', 'Drug: Placebo']}], 'interventions': [{'name': 'GDC-0853', 'type': 'DRUG', 'otherNames': ['RO7010939'], 'description': 'Participants will receive GDC-0853 at low, mid, or high doses, orally once or twice daily for 12 weeks in Cohort 1 or 2.', 'armGroupLabels': ['Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'Cohort 2: GDC-0853 High Dose']}, {'name': 'Adalimumab', 'type': 'DRUG', 'description': 'Participants will receive adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks.', 'armGroupLabels': ['Cohort 1: GDC-0853 Placebo + Adalimumab']}, {'name': 'Folic Acid', 'type': 'DRUG', 'description': "Participants will receive stable background therapy of folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.", 'armGroupLabels': ['Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'Cohort 2: GDC-0853 High Dose', 'Cohort 2: GDC-0853 Placebo']}, {'name': 'MTX', 'type': 'DRUG', 'description': 'Participants will receive stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines).', 'armGroupLabels': ['Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'Cohort 2: GDC-0853 High Dose', 'Cohort 2: GDC-0853 Placebo']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Participants will receive placebo matched to adalimumab, subcutaneously Q2W and/or placebo matched to GDC-0853, orally once or twice daily for 12 weeks in Cohort 1 or 2.', 'armGroupLabels': ['Cohort 1: GDC-0853 High Dose + Adalimumab Placebo', 'Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo', 'Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo', 'Cohort 1: GDC-0853 Placebo + Adalimumab', 'Cohort 1: GDC-0853 Placebo + Adalimumab Placebo', 'Cohort 2: GDC-0853 Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '36207', 'city': 'Anniston', 'state': 'Alabama', 'country': 'United States', 'facility': 'Pinnacle Research Group; Llc, Central', 'geoPoint': {'lat': 33.65983, 'lon': -85.83163}}, {'zip': '85306', 'city': 'Glendale', 'state': 'Arizona', 'country': 'United States', 'facility': 'Arizona Arthritis & Rheumatology Associates, P.C.', 'geoPoint': {'lat': 33.53865, 'lon': -112.18599}}, {'zip': '91723', 'city': 'Covina', 'state': 'California', 'country': 'United States', 'facility': 'Medvin Clinical Research', 'geoPoint': {'lat': 34.09001, 'lon': -117.89034}}, {'zip': '92020', 'city': 'El Cajon', 'state': 'California', 'country': 'United States', 'facility': 'TriWest Research Associates, LLC', 'geoPoint': {'lat': 32.79477, 'lon': -116.96253}}, {'zip': '92835', 'city': 'Fullerton', 'state': 'California', 'country': 'United States', 'facility': 'Saint Jude Heritage Medical Grp', 'geoPoint': {'lat': 33.87029, 'lon': -117.92534}}, {'zip': '94305-5151', 'city': 'Stanford', 'state': 'California', 'country': 'United States', 'facility': 'Stanford University School of Medicine', 'geoPoint': {'lat': 37.42411, 'lon': -122.16608}}, {'zip': '33486', 'city': 'Boca Raton', 'state': 'Florida', 'country': 'United States', 'facility': 'RASF-Clinical Research Center', 'geoPoint': {'lat': 26.35869, 'lon': -80.0831}}, {'zip': '33472', 'city': 'Boynton Beach', 'state': 'Florida', 'country': 'United States', 'facility': 'ZASA Clinical Research', 'geoPoint': {'lat': 26.52535, 'lon': -80.06643}}, {'zip': '33765', 'city': 'Clearwater', 'state': 'Florida', 'country': 'United States', 'facility': 'Clinical Research of West Florida', 'geoPoint': {'lat': 27.96585, 'lon': -82.8001}}, {'zip': '33136', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'InVentiv Health', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '32810', 'city': 'Orlando', 'state': 'Florida', 'country': 'United States', 'facility': 'Omega Research Consultants', 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'zip': '33613', 'city': 'Tampa', 'state': 'Florida', 'country': 'United States', 'facility': 'McIlwain Medical Group', 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'zip': '83404', 'city': 'Idaho Falls', 'state': 'Idaho', 'country': 'United States', 'facility': 'Institute of Arthritis Research', 'geoPoint': {'lat': 43.46658, 'lon': -112.03414}}, {'zip': '83642', 'city': 'Meridian', 'state': 'Idaho', 'country': 'United States', 'facility': 'Advanced Clinical Research', 'geoPoint': {'lat': 43.61211, 'lon': -116.39151}}, {'zip': '27408', 'city': 'Greensboro', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Medication Management', 'geoPoint': {'lat': 36.07264, 'lon': -79.79198}}, {'zip': '97239', 'city': 'Portland', 'state': 'Oregon', 'country': 'United States', 'facility': 'Oregon Health and Science University', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'zip': '19610', 'city': 'Wyomissing', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Clinical Research Center of Reading', 'geoPoint': {'lat': 40.32954, 'lon': -75.96521}}, {'zip': '75231', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'Metroplex Clinical Research', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '75246', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'Baylor Research Inst.', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '77004', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Accurate Clinical Management - VO', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '77089', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Accurate Clinical Research', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '77901', 'city': 'Victoria', 'state': 'Texas', 'country': 'United States', 'facility': 'Crossroads Clinical Research, LLC', 'geoPoint': {'lat': 28.80527, 'lon': -97.0036}}, {'zip': '24541', 'city': 'Danville', 'state': 'Virginia', 'country': 'United States', 'facility': 'Danville Orthopedic Clinic, Inc.; Research Department', 'geoPoint': {'lat': 36.58597, 'lon': -79.39502}}, {'zip': 'B7600FZN', 'city': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Instituto de Investigaciones Clinicas-Mar del Plata', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': 'C1015ABO', 'city': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Organizacion Medica de Investigacion', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': 'C1181ACH', 'city': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Hospital Italiano', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': 'C1194AAO', 'city': 'Buenos Aires', 'country': 'Argentina', 'facility': 'APRILLUS', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': 'C1204AAD', 'city': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Instituto centenario', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': 'C1055AAF', 'city': 'Ciudad Autonoma Buenos Aires', 'country': 'Argentina', 'facility': 'Centro de Investigacion en Enfermedades Reumaticas CIER'}, {'zip': 'C1128AAE', 'city': 'Ciudad Autonoma Buenos Aires', 'country': 'Argentina', 'facility': 'Expertia S.A- Mautalen Salud e Investigación'}, {'zip': 'C1430CKE', 'city': 'Ciudad Autonoma Buenos Aires', 'country': 'Argentina', 'facility': 'CCBR - Buenos Aires - AR; AxisMed SRL'}, {'zip': 'X5000BNB', 'city': 'Córdoba', 'country': 'Argentina', 'facility': 'ILAIM-CEOM Inst. Latinoamericano de Inv. Medicas', 'geoPoint': {'lat': -31.40648, 'lon': -64.18853}}, {'zip': '1900', 'city': 'La Plata', 'country': 'Argentina', 'facility': 'Hospital Italiano de La Plata', 'geoPoint': {'lat': -34.92126, 'lon': -57.95442}}, {'zip': 'B7600DHK', 'city': 'Mar del Plata', 'country': 'Argentina', 'facility': 'Centro de Investigaciones Medicas Mar Del Plata', 'geoPoint': {'lat': -38.00042, 'lon': -57.5562}}, {'zip': '1878', 'city': 'Quilmes', 'country': 'Argentina', 'facility': 'Instituto de Investigaciones Clínicas Quilmes', 'geoPoint': {'lat': -34.72065, 'lon': -58.25454}}, {'zip': '5400', 'city': 'San Juan', 'country': 'Argentina', 'facility': 'CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica', 'geoPoint': {'lat': -31.53726, 'lon': -68.52568}}, {'zip': 'T4000AXL', 'city': 'San Miguel', 'country': 'Argentina', 'facility': 'Centro Medico Privado de Reumatologia; Reumathology', 'geoPoint': {'lat': -34.54335, 'lon': -58.71229}}, {'zip': '74110-120', 'city': 'Goiânia', 'state': 'Goiás', 'country': 'Brazil', 'facility': 'CIP - Centro Internacional de Pesquisa; Pesquisa Clinica', 'geoPoint': {'lat': -16.67861, 'lon': -49.25389}}, {'zip': '36036-330', 'city': 'Juiz de Fora', 'state': 'Minas Gerais', 'country': 'Brazil', 'facility': 'Centro Mineiro de Pesquisa - CMIP', 'geoPoint': {'lat': -21.76417, 'lon': -43.35028}}, {'zip': '80440-080', 'city': 'Curitiba', 'state': 'Paraná', 'country': 'Brazil', 'facility': 'Edumed - Educação e Saúde SA', 'geoPoint': {'lat': -25.42778, 'lon': -49.27306}}, {'zip': '80030-110', 'city': 'Curtiba', 'state': 'Paraná', 'country': 'Brazil', 'facility': 'Centro de Estudos em Terapias Inovadoras - CETI'}, {'zip': '22271-100', 'city': 'Rio de Janeiro', 'state': 'Rio de Janeiro', 'country': 'Brazil', 'facility': 'CCBR - Synarc Centro de Pesquisa Clinica - RJ', 'geoPoint': {'lat': -22.90642, 'lon': -43.18223}}, {'zip': '99010-090', 'city': 'Passo Fundo', 'state': 'Rio Grande do Sul', 'country': 'Brazil', 'facility': 'Hospital Sao Vicente de Paulo', 'geoPoint': {'lat': -28.26278, 'lon': -52.40667}}, {'zip': '90480-000', 'city': 'Porto Alegre', 'state': 'Rio Grande do Sul', 'country': 'Brazil', 'facility': 'LMK Serviços Médicos S/S', 'geoPoint': {'lat': -30.03283, 'lon': -51.23019}}, {'zip': '13087-567', 'city': 'Campinas', 'state': 'São Paulo', 'country': 'Brazil', 'facility': 'CAEP - Centro Avancado de Estudos e Pesquisas Ltda.', 'geoPoint': {'lat': -22.90556, 'lon': -47.06083}}, {'zip': '09060-650', 'city': 'Santo André', 'state': 'São Paulo', 'country': 'Brazil', 'facility': 'Faculdade de Medicina do ABC - FMABC', 'geoPoint': {'lat': -23.66389, 'lon': -46.53833}}, {'zip': '15090-000', 'city': 'São José do Rio Preto', 'state': 'São Paulo', 'country': 'Brazil', 'facility': 'Fundação Faculdade Regional de Medicina de São José do Rio Preto', 'geoPoint': {'lat': -20.81972, 'lon': -49.37944}}, {'zip': '01244-030', 'city': 'São Paulo', 'state': 'São Paulo', 'country': 'Brazil', 'facility': 'CPCLIN - Centro de Pesquisas Clínicas Ltda.; Pesquisa Clinica', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'zip': '05437-010', 'city': 'São Paulo', 'state': 'São Paulo', 'country': 'Brazil', 'facility': 'Instituto de Pesquisa Clínica e Medicina Avançada Ltda', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'zip': '9300', 'city': 'Dobrich', 'country': 'Bulgaria', 'facility': 'MHAT - Dobrich, AD', 'geoPoint': {'lat': 43.56491, 'lon': 27.83138}}, {'zip': '4002', 'city': 'Plovdiv', 'country': 'Bulgaria', 'facility': 'MHAT "Eurohospital" - Plovdiv, OOD', 'geoPoint': {'lat': 42.15387, 'lon': 24.75001}}, {'zip': '4002', 'city': 'Plovdiv', 'country': 'Bulgaria', 'facility': 'MHAT Kaspela; EOOD', 'geoPoint': {'lat': 42.15387, 'lon': 24.75001}}, {'zip': '7002', 'city': 'Rousse', 'country': 'Bulgaria', 'facility': 'MHAT - Ruse, AD', 'geoPoint': {'lat': 43.84872, 'lon': 25.9534}}, {'zip': '5400', 'city': 'Sevlievo', 'country': 'Bulgaria', 'facility': 'Medizinski Zentrar-1-Sevlievo EOOD', 'geoPoint': {'lat': 43.02295, 'lon': 25.10364}}, {'zip': '8800', 'city': 'Sliven', 'country': 'Bulgaria', 'facility': 'MHAT "Hadzhi Dimitar", OOD', 'geoPoint': {'lat': 42.68607, 'lon': 26.32558}}, {'zip': '1000', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'Medical Center Excelsior OOD', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '1233', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'NMTH "Tsar Boris III"', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '1336', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'MHAT "Lyulin", EAD', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '1431', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'DCC "Alexandrovska", EOOD; Clinic of Neurology', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '1750', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'UMHAT "SofiaMed", OOD', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '1784', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'MC "Synexus - Sofia", EOOD', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '6003', 'city': 'Stara Zagora', 'country': 'Bulgaria', 'facility': 'MHAT Dr. St. Kirkovich, AD', 'geoPoint': {'lat': 42.43205, 'lon': 25.64262}}, {'zip': '3000', 'city': 'Vratsa', 'country': 'Bulgaria', 'facility': "'New Medical Center' , EOOD", 'geoPoint': {'lat': 43.21052, 'lon': 23.56312}}, {'zip': '80020', 'city': 'Barranquilla', 'country': 'Colombia', 'facility': 'Centro de Reumatologia y Ortopedia', 'geoPoint': {'lat': 10.96854, 'lon': -74.78132}}, {'zip': '110221', 'city': 'Bogotá', 'country': 'Colombia', 'facility': 'Centro de Investigacion en Reumatologia y Especialdades Medicas SAS. CIREEM', 'geoPoint': {'lat': 4.60971, 'lon': -74.08175}}, {'zip': '110221', 'city': 'Bogotá', 'country': 'Colombia', 'facility': 'Riesgo de Fractura S.A.', 'geoPoint': {'lat': 4.60971, 'lon': -74.08175}}, {'zip': '111211', 'city': 'Bogotá', 'country': 'Colombia', 'facility': 'Fundación Instituto de Reumatología Fernando Chalem', 'geoPoint': {'lat': 4.60971, 'lon': -74.08175}}, {'zip': '00000', 'city': 'Cali', 'country': 'Colombia', 'facility': 'Clinica de Artritis Temprana S.A.', 'geoPoint': {'lat': 3.43054, 'lon': -76.5199}}, {'zip': '050034', 'city': 'Medellín', 'country': 'Colombia', 'facility': 'Hospital Pablo Tobon Uribe', 'geoPoint': {'lat': 6.245, 'lon': -75.57151}}, {'zip': '62170', 'city': 'Cuernavaca', 'state': 'Morelos', 'country': 'Mexico', 'facility': 'Consultorio Medico en Fundacion el Hospitalito de morelos A.C.', 'geoPoint': {'lat': 18.9261, 'lon': -99.23075}}, {'zip': '80000', 'city': 'Culiacán', 'state': 'Sinaloa', 'country': 'Mexico', 'facility': 'Centro de Investigación de Tratamientos Innovadores de Sinaloa (CITI)', 'geoPoint': {'lat': 24.80209, 'lon': -107.39421}}, {'zip': '97070', 'city': 'Mérida', 'state': 'Yucatán', 'country': 'Mexico', 'facility': 'Centro de Investigacion en Reumatologia', 'geoPoint': {'lat': 20.967, 'lon': -89.62318}}, {'zip': '62290', 'city': 'Cuernavaca', 'country': 'Mexico', 'facility': 'Consultorio Particular del Dr. Miguel Cortes Hernandez', 'geoPoint': {'lat': 18.9261, 'lon': -99.23075}}, {'zip': '21100', 'city': 'Mexicali', 'country': 'Mexico', 'facility': 'Centro de Investigacion en Enfermedades Reumaticas y Osteoporosis', 'geoPoint': {'lat': 32.62781, 'lon': -115.45446}}, {'zip': '03720', 'city': 'México', 'country': 'Mexico', 'facility': 'Centro de Investigacion Clínica GRAMEL S.C', 'geoPoint': {'lat': 31.00435, 'lon': -108.15213}}, {'zip': '76000', 'city': 'Querétaro', 'country': 'Mexico', 'facility': 'Policilinica Medica de Queretaro; Rheumatology', 'geoPoint': {'lat': 15.83752, 'lon': -92.75774}}, {'zip': '54055', 'city': 'Tlalnepantla', 'country': 'Mexico', 'facility': 'Clinical Research Institute', 'geoPoint': {'lat': 19.54005, 'lon': -99.19538}}, {'zip': '27000', 'city': 'Torreón', 'country': 'Mexico', 'facility': 'Unidad de Enfermedades Reumaticas y Cronicodegenerativas', 'geoPoint': {'lat': 25.54389, 'lon': -103.41898}}, {'zip': '15-351', 'city': 'Bialystok', 'country': 'Poland', 'facility': 'NZOZ OSTEO-MEDIC S.C. Artur Racewicz, Jerzy Supronik', 'geoPoint': {'lat': 53.13333, 'lon': 23.16433}}, {'zip': '85-168', 'city': 'Bydgoszcz', 'country': 'Poland', 'facility': 'Szpital Uniwersytecki; nr 2 im. Dr J. Biziela', 'geoPoint': {'lat': 53.1235, 'lon': 18.00762}}, {'zip': '40-081', 'city': 'Katowice', 'country': 'Poland', 'facility': 'Medica Pro Familia Spolka Akcyjna Oddzial w Katowicach', 'geoPoint': {'lat': 50.2597, 'lon': 19.02173}}, {'zip': '30-349', 'city': 'Krakow', 'country': 'Poland', 'facility': 'Centrum Medyczne Plejady', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'zip': '90-368', 'city': 'Lodz', 'country': 'Poland', 'facility': 'CCBR - Lodz - PL', 'geoPoint': {'lat': 51.77058, 'lon': 19.47395}}, {'zip': '10-117', 'city': 'Olsztyn', 'country': 'Poland', 'facility': 'ETYKA Osrodek Badan Kliniczynch', 'geoPoint': {'lat': 53.78376, 'lon': 20.49272}}, {'zip': '61-113', 'city': 'Poznan', 'country': 'Poland', 'facility': 'Ai Centrum Medyczne Sp. Z O.O Sp.K.', 'geoPoint': {'lat': 52.40692, 'lon': 16.92993}}, {'zip': '28-200', 'city': 'Staszów', 'country': 'Poland', 'facility': 'KO-MED Centra Kliniczne Staszow', 'geoPoint': {'lat': 50.56307, 'lon': 21.16593}}, {'zip': '00-660', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Medycyna Kliniczna', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '03-291', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Centrum Medyczne AMED', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '51-124', 'city': 'Wroclaw', 'country': 'Poland', 'facility': 'Wojewódzki Szpital Specjalistyczny we Wrocławiu', 'geoPoint': {'lat': 51.10286, 'lon': 17.03006}}, {'zip': '22400', 'city': 'Zamość', 'country': 'Poland', 'facility': 'KO-MED Centra Kliniczne Zamosc', 'geoPoint': {'lat': 50.72314, 'lon': 23.25196}}, {'zip': '660062', 'city': 'Krasnoyarsk', 'state': 'Krasnoyarsk Krai', 'country': 'Russia', 'facility': 'TSBIH "Krasnoyarsk Interdistrict Clinical Hospital of Emergency Medical Care n.a. N.S. Karpovich', 'geoPoint': {'lat': 56.03742, 'lon': 92.93136}}, {'zip': '115522', 'city': 'Moscow', 'state': 'Moscow Oblast', 'country': 'Russia', 'facility': 'Federal State Budgetary Scientific Institution Research Institute of Rheumatology V.A. Nasonova'}, {'zip': '119049', 'city': 'Moscow', 'state': 'Moscow Oblast', 'country': 'Russia', 'facility': 'SBIH of Moscow "City Clinical Hospital # 1 n. a. N. I. Pirogov"'}, {'zip': '119992', 'city': 'Moscow', 'state': 'Moscow Oblast', 'country': 'Russia', 'facility': 'SBEI HPE " First Moscow State Medical University n.a. I.M. Sechenov" of the MoH of the RF'}, {'zip': '191144', 'city': 'Saint Petersburg', 'state': 'Sankt-Peterburg', 'country': 'Russia', 'facility': 'Technologii zdorovia LLC', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '195257', 'city': 'Saint Petersburg', 'state': 'Sankt-Peterburg', 'country': 'Russia', 'facility': 'Sanavita LLC', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '196066', 'city': 'Saint Petersburg', 'state': 'Sankt-Peterburg', 'country': 'Russia', 'facility': 'LLC Medical Sanitary Unit', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '620043', 'city': 'Yekaterinburg', 'state': 'Sankt-Peterburg', 'country': 'Russia', 'facility': 'Center of Family Medicine LC'}, {'zip': '150051', 'city': 'Yaroslavl', 'state': 'Volgograd Oblast', 'country': 'Russia', 'facility': 'SBHI of Yaroslavl Region Clinical Hospital #3'}, {'zip': '454076', 'city': 'Chelyabinsk', 'state': 'Voronez', 'country': 'Russia', 'facility': 'SMMIH "Chelyabinsk Regional Clinical Hospital"', 'geoPoint': {'lat': 55.1611, 'lon': 61.42877}}, {'zip': '650000', 'city': 'Kemerovo', 'country': 'Russia', 'facility': 'SAHI of Kem. "Regional Clinical Hospital for War Veterans"', 'geoPoint': {'lat': 55.35417, 'lon': 86.10435}}, {'zip': '141060', 'city': 'Korolev, Moscow Region', 'country': 'Russia', 'facility': 'OOO Family Polyclinic', 'geoPoint': {'lat': 55.91417, 'lon': 37.82556}}, {'zip': '115404', 'city': 'Moscow', 'country': 'Russia', 'facility': 'Practical Medicine', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'zip': '630091', 'city': 'Novosibirsk', 'country': 'Russia', 'facility': 'Limited Liability Company "Centre of Medical Common Practice"', 'geoPoint': {'lat': 55.02259, 'lon': 82.93175}}, {'zip': '644024', 'city': 'Omsk', 'country': 'Russia', 'facility': 'Ultramed', 'geoPoint': {'lat': 54.99244, 'lon': 73.36859}}, {'zip': '190068', 'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'City Hospital 25; Rheumatology', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '197022', 'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'Pavlov First Saint Petersburg State Medical University', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '410026', 'city': 'Saratov', 'country': 'Russia', 'facility': 'SBEI HPE "Saratov State Medical University n.a. V. I. Razumovskiy" of the MoH of the RF', 'geoPoint': {'lat': 51.54048, 'lon': 45.9901}}, {'zip': '214019', 'city': 'Smolensk', 'country': 'Russia', 'facility': 'SBEI HPE "Smolensk State Medical University" of the MoH of the RF', 'geoPoint': {'lat': 54.77826, 'lon': 32.05088}}, {'zip': '634050', 'city': 'Tomsk', 'country': 'Russia', 'facility': 'Siberian State Medical University', 'geoPoint': {'lat': 56.50049, 'lon': 84.98216}}, {'zip': '432063', 'city': 'Ulyanovsk', 'country': 'Russia', 'facility': 'SHI Ulyanovsk Reg Clinical Hospital', 'geoPoint': {'lat': 54.32824, 'lon': 48.38657}}, {'zip': '690035', 'city': 'Vladivostok', 'country': 'Russia', 'facility': 'Territorial Clinical Hospital #2', 'geoPoint': {'lat': 43.10562, 'lon': 131.87353}}, {'zip': '150062', 'city': 'Yaroslavl', 'country': 'Russia', 'facility': 'SHI Yaroslavl Regional Clinical Hospital', 'geoPoint': {'lat': 57.62987, 'lon': 39.87368}}, {'zip': '11000', 'city': 'Belgrade', 'country': 'Serbia', 'facility': 'Institute of Rheumatology', 'geoPoint': {'lat': 44.80401, 'lon': 20.46513}}, {'zip': '11040', 'city': 'Belgrade', 'country': 'Serbia', 'facility': 'Military Medical Academy', 'geoPoint': {'lat': 44.80401, 'lon': 20.46513}}, {'zip': '34000', 'city': 'Kragujevac', 'country': 'Serbia', 'facility': 'Clinical Center Kragujevac', 'geoPoint': {'lat': 44.01667, 'lon': 20.91667}}, {'zip': '18205', 'city': 'Niška Banja', 'country': 'Serbia', 'facility': 'Institute of Treatment and Rehabilitation "Niska Banja"', 'geoPoint': {'lat': 43.29507, 'lon': 22.0057}}, {'zip': '21000', 'city': 'Novi Sad', 'country': 'Serbia', 'facility': 'Special hospital for rheumatic diseases Novi Sad', 'geoPoint': {'lat': 45.25167, 'lon': 19.83694}}, {'zip': '15000', 'city': 'Šabac', 'country': 'Serbia', 'facility': 'General Hospital Sabac; Department of Urology and Hemodialysis', 'geoPoint': {'lat': 44.74667, 'lon': 19.69}}, {'zip': '35015', 'city': 'Daejeon', 'country': 'South Korea', 'facility': 'Chungnam National University Hospital; Department of Internal Medicine (Rheumatology)', 'geoPoint': {'lat': 36.34913, 'lon': 127.38493}}, {'zip': '61469', 'city': 'Gwangju', 'country': 'South Korea', 'facility': 'Chonnam National University Hospital', 'geoPoint': {'lat': 35.15472, 'lon': 126.91556}}, {'zip': '13620', 'city': 'Gyeonggi-do', 'country': 'South Korea', 'facility': 'Seoul National University Bundang Hospital', 'geoPoint': {'lat': 37.58944, 'lon': 126.76917}}, {'zip': '03080', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Seoul National University Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '05030', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Konkuk University Medical Center', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '05505', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Asan Medical Center - Oncology', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '443-721', 'city': 'Suwon', 'country': 'South Korea', 'facility': 'Ajou University Hospital', 'geoPoint': {'lat': 37.29111, 'lon': 127.00889}}, {'zip': '46002', 'city': 'Ternopil', 'state': 'Kherson Governorate', 'country': 'Ukraine', 'facility': 'CI of TRC', 'geoPoint': {'lat': 49.55404, 'lon': 25.59067}}, {'zip': '76008', 'city': 'Ivano-Frankivsk', 'state': 'KIEV Governorate', 'country': 'Ukraine', 'facility': 'Regional CH Dep of Rheumatology SHEI Ivano-Frankivsk NMU', 'geoPoint': {'lat': 48.92312, 'lon': 24.71248}}, {'zip': '01601', 'city': 'Kyiv', 'state': 'KIEV Governorate', 'country': 'Ukraine', 'facility': 'Medical Center Medical Clinic Blagomed LLC.', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'zip': '02091', 'city': 'Kyiv', 'state': 'KIEV Governorate', 'country': 'Ukraine', 'facility': 'Medical Center OK!Clinic+', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'zip': '03680', 'city': 'Kyiv', 'state': 'KIEV Governorate', 'country': 'Ukraine', 'facility': 'SI NSС M.D. Strazhesko Institute of Cardiology of NAMSU', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'zip': '04071', 'city': 'Kyiv', 'state': 'KIEV Governorate', 'country': 'Ukraine', 'facility': 'Clinic of Modern Rheumatology Revmotsentr LLC', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'zip': '79010', 'city': 'Lviv', 'state': 'KIEV Governorate', 'country': 'Ukraine', 'facility': 'Lviv Regional Clinical Hospital Dept of Rehmuaatology D. Halytskyi Lviv NMU', 'geoPoint': {'lat': 49.83826, 'lon': 24.02324}}, {'zip': '79014', 'city': 'Lviv', 'state': 'KIEV Governorate', 'country': 'Ukraine', 'facility': 'CH of State Border Service of Ukraine (Military Base 2522); Dept of Therapy, D.Halytskyi Lviv NMU', 'geoPoint': {'lat': 49.83826, 'lon': 24.02324}}, {'zip': '88018', 'city': 'Uzhhorod', 'state': 'KIEV Governorate', 'country': 'Ukraine', 'facility': 'A.Novak Transcarpathian Regional Clinical Hospital', 'geoPoint': {'lat': 48.6242, 'lon': 22.2947}}, {'zip': '49008', 'city': 'Dnipro', 'state': 'Tavria Okruha', 'country': 'Ukraine', 'facility': 'Railway Transp DCH of HealthCenter Branch of PJSC Ukr Railway Dept of Rheumatology', 'geoPoint': {'lat': 48.46664, 'lon': 35.04066}}, {'zip': '61039', 'city': 'Kharkiv', 'country': 'Ukraine', 'facility': 'GI L.T.Malaya Therapy National Institute of the NAMS of Ukraine', 'geoPoint': {'lat': 49.98177, 'lon': 36.25475}}, {'zip': '61176', 'city': 'Kharkiv', 'country': 'Ukraine', 'facility': 'Kharkiv MA of PGE of MOHU Ch of Cardiology and Functional Diagnostics', 'geoPoint': {'lat': 49.98177, 'lon': 36.25475}}, {'zip': '02232', 'city': 'Kyiv', 'country': 'Ukraine', 'facility': 'CNI Consultative and Diagnostic Center of Desnianskyi District of Kyiv', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'zip': '04107', 'city': 'Kyiv', 'country': 'Ukraine', 'facility': 'MI of Helathcare Kyiv RCH P.L. Shupy NMA of PGE', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'zip': '04114', 'city': 'Kyiv', 'country': 'Ukraine', 'facility': 'Gerontology Institute of the Ukrainian AMS', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'zip': '1023', 'city': 'Kyiv', 'country': 'Ukraine', 'facility': 'Oleksandrivska Clinical Hospital', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'zip': '43024', 'city': 'Lutsk', 'country': 'Ukraine', 'facility': 'Volyn Regional Center of Cardiovascular Pathology and Thrombolysis', 'geoPoint': {'lat': 50.75784, 'lon': 25.35024}}, {'zip': '54003', 'city': 'Mykolaiv', 'country': 'Ukraine', 'facility': 'City Hospital #1', 'geoPoint': {'lat': 49.52659, 'lon': 23.98138}}, {'zip': '36011', 'city': 'Poltava', 'country': 'Ukraine', 'facility': 'M.V. Sklifosovsky Poltava RCH Dept of Rheumatology HSEIU UMSA', 'geoPoint': {'lat': 49.58925, 'lon': 34.55367}}, {'zip': '21001', 'city': 'Vinnytsia', 'country': 'Ukraine', 'facility': 'Private Small Enterprise Medical Center Pulse', 'geoPoint': {'lat': 49.2322, 'lon': 28.46871}}, {'zip': '21018', 'city': 'Vinnytsia', 'country': 'Ukraine', 'facility': 'M.I. Pyrogov VRCH Dept of Gastroenterology M.I. Pyrogov VNMU', 'geoPoint': {'lat': 49.2322, 'lon': 28.46871}}, {'zip': '69096', 'city': 'Zaporizhzhia', 'country': 'Ukraine', 'facility': 'City Clinical Hospital #9 Dept of Gastrosurgery SI Zaporizhzhia MA of PGE of MoHU', 'geoPoint': {'lat': 47.15214, 'lon': 35.74246}}, {'zip': '69118', 'city': 'Zaporizhzhia', 'country': 'Ukraine', 'facility': 'CI City Hospital #7', 'geoPoint': {'lat': 47.15214, 'lon': 35.74246}}, {'zip': '69600', 'city': 'Zaporizhzhia', 'country': 'Ukraine', 'facility': 'CI Zaporizhzhia Regional Clinical Hospital of ZRC', 'geoPoint': {'lat': 47.15214, 'lon': 35.74246}}], 'overallOfficials': [{'name': 'Clinical Trials', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Hoffmann-La Roche'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Genentech, Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}